Roseburia intestinalis

What was studied?

This randomized, double-blind, placebo-controlled trial tested whether daily supplementation with two specific probiotic strains, Bifidobacterium animalis subsp. lactis XLTG11 and Lactiplantibacillus plantarum CCFM8661, could reduce recurrent respiratory tract infections (RRTIs) in children. Over 180 days, the study tracked infection frequency and duration alongside changes in gut microbiota composition, functional metabolic pathways, and immune biomarkers. The design allowed the researchers to link clinical respiratory outcomes to underlying shifts in the gut microbial community and immune regulation.

Who was studied?

The study enrolled 120 children who had been diagnosed with recurrent respiratory tract infections. Participants were randomly assigned to receive either the probiotic combination or a matched placebo daily for 180 days. The abstract does not provide further demographic details such as age range or sex distribution.

What were the most important findings?

Children receiving the probiotics had significantly reduced duration and frequency of fever, cough, upper respiratory tract infections, trachea or bronchitis, pneumonia, and overall RRTI recurrence compared with placebo (all p < 0.05). Gut microbiota profiling at day 180 showed clear community differences between groups, with the probiotic group showing greater abundance of beneficial commensal taxa and the placebo group showing more opportunistic genera. Functional pathway analysis pointed to enhanced metabolic stability in the probiotic recipients, and immune biomarker patterns showed comparatively stable IgG, IgM, and complement C3 levels, suggesting a more regulated humoral immune response. Growth trajectories remained normal in both groups.

What are the greatest implications of this study?

These findings support strain-defined probiotic supplementation as a viable adjunct strategy for reducing the burden of recurrent respiratory infections in children. The parallel shifts in gut microbial composition, metabolic function, and humoral immune stability suggest the respiratory benefit may be mediated through gut-immune axis modulation rather than a direct respiratory-tract effect. Because growth remained normal, the intervention appears well tolerated over a six-month period, supporting its potential for longer-term pediatric preventive use pending further confirmatory trials.

What was studied?

This study examined whether alterations in the gut microbiome track the development of Parkinson's disease (PD) in people who carry GBA1 gene variants but have not (yet) developed PD symptoms. The researchers combined clinical data with fecal metagenomics and used an analysis method that assessed both differential abundance of microbial species and the coherence of that abundance variation across groups, measured with Cliff's delta. The goal was to determine whether microbiome composition could serve as an early marker of PD risk in genetically at-risk individuals.

Who was studied?

The primary cohort included 271 patients with PD, 43 carriers of GBA1 variants who had not developed PD symptoms (GBA-NMC), and 150 healthy controls. Findings were then checked against three independent cohorts from the United States, Korea, and Turkey, together comprising 638 additional PD patients and 319 additional healthy controls. In total, the study drew on clinical and fecal metagenomic data from close to 1,400 individuals across four countries.

What were the most important findings?

About 25% of the gut microbiome in GBA-NMC individuals showed a composition that was intermediate between healthy controls and patients with PD. This intermediate microbiome signature was strongly correlated with disease progression in patients who already had PD, and with prodromal symptoms suggestive of future PD in both GBA-NMC and healthy individuals. Similar microbiome alterations were reproduced across the three independent international cohorts, strengthening confidence that the pattern is not specific to one population.

What are the greatest implications of this study?

The findings suggest gut microbiome changes can flag both genetically at-risk (GBA1 carriers) and non-genetically at-risk people in the general population who may be on a trajectory toward developing PD. This positions the microbiome as a potential early, non-invasive marker during the premanifest phase of disease, before clinical symptoms appear. Such a marker could eventually help identify candidates for early monitoring or intervention trials aimed at delaying or preventing PD onset.

What was studied?

This study investigated the effects of a novel elite athlete derived probiotic, a multi-strain Lactobacillus consortium, on sleep quality, exercise recovery, and gut microbiome composition. The researchers used a two phase design: an open-label study followed by a controlled longitudinal study. Multi-omics analyses were used to examine changes in microbiome composition and function alongside host physiological markers.

Who was studied?

The study included elite athletes (n = 11), specifically a professional soccer team for the controlled longitudinal phase, and a general population sample (n = 257) in the open-label phase. This dual-cohort design allowed comparison between high-performance athletes and a broader nonathlete population. No further demographic details are given in the abstract.

What were the most important findings?

In the placebo-controlled study, probiotic intervention was associated with significant improvements in self-reported sleep quality (69%), energy levels (31%), and bowel movements (37%) relative to placebo. These improvements coincided with a significant decrease in D-ROMS, a marker of oxidative stress, and a significantly higher free-testosterone to cortisol ratio. Multi-omics analyses revealed specific changes in gut microbiome composition and function that may help explain these host effects.

What are the greatest implications of this study?

The findings suggest that a targeted Lactobacillus consortium can meaningfully influence sleep, energy, recovery-related hormone balance, and oxidative stress through gut microbiome-mediated mechanisms. This supports the gut microbiome as a plausible intervention point connecting sleep and exercise recovery in both elite athletes and the general population. The multi-omics insights point toward mechanistic pathways that could inform future probiotic formulations aimed at recovery and wellness.

What was studied?

Wild animals face numerous challenges in less ideal habitats, including the lack of food as well as changes in diet. Understanding how the gut microbiomes of wild animals adapt to changes in food resources within suboptimal habitats is critical for their survival. Therefore, we conducted a longitudinal sampling of three gibbon species living in high-quality (Nomascus hainanus) and suboptimal (Nomascus concolor and Hoolock tianxing) habitats to address the dynamics of gut microbiome assembly over one year. The three gibbon species exhibited significantly different gut microbial diversity and composition. N. hainanus showed the lowest alpha diversity and highest nestedness, suggesting a more specialized and potentially stable microbial community in terms of composition, while H. tianxing displayed high species turnover and low nestedness, reflecting a more dynamic microbial ecosystem, which may indicate greater sensitivity to environmental changes or a flexible response to habitat variability. The gut microbial community of N. concolor was influenced by homogeneous selection in the deterministic process, primarily driven by Prevotellaceae. In contrast, the gut microbial communities of H. tianxing and N. hainanus were influenced by dispersal limitation in the stochastic process, driven by Acholeplasmataceae and Fibrobacterota, respectively. Further, the microbial response patterns to leaf feeding in N. hainanus differed from those of the other two gibbon species. In conclusion, this first cross-species comparative study provides initial insights into the different ecological adaptive strategies of gut microbiomes from a point of community assembly, which could contribute to the long-term conservation of wild primates. In this study, we conducted longitudinal sampling of three gibbon species living in high-quality (Nomascus hainanus) and suboptimal (Nomascus concolor and Hoolock tianxing) habitats to address the dynamics of gut microbiome (composition, alpha diversity, beta diversity and assembly process) over one year.

What was studied?

This study investigated Roseburia hominis as a novel candidate probiotic (next-generation live biotherapeutic) for treating obesity and related metabolic disease. The researchers first examined how R. hominis abundance related to obesity status, then tested whether supplementing R. hominis could prevent metabolic disturbances in a diet-induced obesity model. They also explored a possible mechanism involving nicotinamide riboside production and Sirtuin1/mTOR signaling.

Who was studied?

The abstract describes stool samples compared between obese subjects and lean controls, indicating a human cohort used to establish the association between R. hominis abundance and body mass index and serum triglycerides. The interventional portion of the study was conducted in mice fed a high-fat diet to model diet-induced obesity. Specific numbers of human subjects or mice, and demographic details, are not given in the abstract.

What were the most important findings?

Roseburia hominis was depleted in the stool of obese subjects compared with lean controls, and its abundance was negatively correlated with body mass index and serum triglycerides. In high-fat-diet mice, supplementing R. hominis prevented body weight gain, corrected glucose and lipid metabolism disorders, prevented fatty liver, inhibited white adipose tissue expansion, and reduced brown adipose tissue whitening, while boosting lean-associated microbial species. These effects were linked in part to R. hominis production of nicotinamide riboside and upregulation of the Sirtuin1/mTOR signaling pathway.

What are the greatest implications of this study?

The findings position Roseburia hominis as a promising next-generation live biotherapeutic candidate for preventing obesity and metabolic disease. Because its depletion tracks with obesity and adverse metabolic markers in humans, restoring this commensal species could represent a targeted microbiome-based strategy rather than a broad-spectrum probiotic approach. The nicotinamide riboside and Sirtuin1/mTOR mechanism offers a specific pathway for further mechanistic and translational research.

What was studied?

UNLABELLED: Pulmonary tuberculosis (PTB) and diabetes mellitus (DM) are prevalent chronic diseases with substantial implications for human health. DM patients are more susceptible to PTB, which exacerbates diabetes-related complications. However, the complex molecular mechanisms underlying the enhanced susceptibility of DM patients to PTB infection remain poorly understood. In this study, α- and β-diversity of gut microbiota was significantly reduced in PTB patients and PTB-DM patients. The abundances of families Lachnospiraceae and Ruminococcaceae in the the Firmicutes phylum were reduced in PTB patients and further diminished in PTB-DM patients. On the other hand, untargeted metabolomics in frozen serum and stool samples indicated that phenylalanine, tyrosine, and tryptophan biosynthesis, metabolites of arginine, proline, tryptophan, and histidine were consistently altered in PTB patients and PTB-DM patients, with significant upregulation of most metabolites. Amino acids like serine, proline, and histidine were both remarkably elevated in PTB and PTB-DM patients. The correlation network analysis reveals the relationships between the shared microbial biomarkers and the shared metabolic pathways. This research contributes to the exploration of pivotal diagnostic biomarkers for both patients with PTB and PTB accompanied by diabetes. Specifically, shared reductions were identified in the genera g-Roseburia, g-Ruminococcaceae_UCG.013, g-Ruminococcaceae_NK4A214, g-Lachnospiraceae_unclassified, and g-Firmicutes_unclassified in addition to notable regulation of amino acids, like glycine, serine, and histidine in patients with PTB and PTB-DM. Our study expands the comprehension of the intricate connections linking gut microbiota, fecal metabolites, and serum metabolites in PTB and PTB-DM patients. IMPORTANCE: This study expands the understanding of the complex links between gut microbiota, fecal metabolites, and serum metabolites in patients with PTB and PTB-DM through multi-omics techniques. It is helpful for us to understand the complex molecular mechanism of increased susceptibility to PTB infection in diabetic patients.

What was studied?

Species in the family Canidae occupy different spatial ecological niches, and some (e.g., wolf) can be kept in zoos. The gut microbiome may differ among various wild and captive canids. Therefore, we compared the gut microbiomes of wild canids (wolf, red fox, and corsac fox) in the Hulun Lake area, captive wolves, and domestic dogs in different regions using metagenomic data. A random forest analysis revealed significant enrichment for bacterial species producing short-chain fatty acids and the thermogenesis pathway (ko04714) in the gut microbiome of wild wolf, potentially providing sufficient energy for adaptation to a wide range of spatial ecological niches. The significantly enriched bacterial species and functional pathways in the gut microbiome of corsac foxes were related to physiological stability and adaptation to arid environments. Alpha diversity of carbohydrate-active enzymes in the gut microbiome was higher in the red fox than in the corsac fox and wild wolf, which may be related to the abundance of plant seeds (containing carbohydrates) in their diets (red foxes inhabit seed-rich willow bosk habitats). However, the influence of host genetic factors cannot be excluded, and further experimental studies are needed to verify the study results. In addition, captive environments drove similarity in carbohydrate-active enzymes (CAZymes) and virulence factors (VFs) in the gut microbiomes of captive wolf and domestic dog, and increased the diversity of CAZymes and VFs in the gut microbiome of captive wolf. Increased VFs diversity may increase the pathogenic potential of the gut microbiome in captive wolves. Therefore, it is necessary to continue monitoring the health status of captive wolves and develop appropriate management strategies.

What was studied?

Metabolic syndrome (MS) and type 2 diabetes (T2D) are metabolically related diseases with rising global prevalence and increasingly evident links to the intestinal microbiota. Research suggests that imbalances in microbiota composition may play a crucial role in their pathogenesis. Specific population cohorts, such as the one in Galicia, Spain, offer the opportunity to analyze microbiota patterns within a distinct geographical and genetic context. This study was performed to investigate the relationship between the intestinal microbiota and MS and T2D.

Who was studied?

A cohort of 79 volunteers was analyzed over a 2-year study period. Recruitment posed significant challenges because of strict inclusion criteria (918PTE0540; PCI2018-093284), which required participants to be free from chronic medications and have a moderate to high risk of developing T2D. Volunteers were classified based on their serum glucose levels, body mass index, and the presence or absence of MS. To analyze the microbiota composition, amplicon sequencing of 16S rRNA genes was performed on stool samples. Alpha diversity was assessed using the Chao and Shannon indices, while beta diversity was evaluated using permutational analysis of variance with Bray-Curtis and Chao distances. Differential abundance analysis was conducted using the LinDA method.

What were the most important findings?

In patients with MS, we observed a higher Firmicutes/Bacteroidetes ratio and an increased prevalence of Blautia compared to healthy patients. than in healthy individuals. Other enriched taxa in patients with MS included Tyzerella, Streptococcus, and Ruminococcus callidus. In patients with T2D, we observed a higher Bacteroidetes/Firmicutes ratio and a decrease in the phylum Actinobacteria compared with healthy individuals. Taxa such as Dorea, Prevotella, Dialister invisus, Fusicatenibacter, and Coprococcus were associated with T2D, while beneficial taxa such as Eubacterium, Ligilactobacillus, and Acidaminococcus were more prevalent in healthy or prediabetic individuals.

What are the greatest implications of this study?

This study reveals notable differences in the intestinal microbiota composition among patients with MS and T2D. Changes in microbial composition, particularly the Firmicutes/Bacteroidetes ratio, may serve as indicators of underlying pathology. At more specific taxonomic levels, several enriched taxa were identified in patients with MS, including Blautia, Tyzzerella, Dorea, Streptococcus, and Ruminococcus callidus. Additionally, species such as Dorea longicatena and Dialister invisus were enriched in prediabetic and diabetic patients, whereas beneficial genera (Eubacterium, Acidaminococcus, Bifidobacterium, and Ligilactobacillus) were more prevalent in healthy and prediabetic individuals than in those with T2D.

What was studied?

This study investigated whether gut microbiota composition and plasma metabolic profiles are altered in lymph node tuberculosis (LNTB), a form of tuberculosis whose relationship with gut microbiota had not previously been explored. Researchers used metagenomic sequencing to characterize gut microbial diversity and composition, paired with plasma metabolomics to assess circulating metabolite changes. KEGG pathway analysis was applied to link microbial gene content to metabolic function, focusing especially on short-chain fatty acid (SCFA) biosynthesis. An integrated analysis then examined correlations between specific gut bacteria and plasma metabolites in LNTB.

Who was studied?

The abstract does not report specific participant numbers, ages, or geographic setting. It indicates a comparison between individuals diagnosed with lymph node tuberculosis (the LNTB group) and healthy individuals serving as controls. Samples analyzed included gut microbiota (via metagenomic sequencing) and plasma (via metabolomics) from these two groups.

What were the most important findings?

LNTB patients showed significantly altered gut microbial diversity, with notable reductions in SCFA-producing taxa including Ruminococcus, Faecalibacterium, Roseburia, and Blautia compared to healthy individuals. KEGG pathway analysis indicated that this gut dysbiosis negatively affected SCFA biosynthesis and metabolism. Plasma metabolomics revealed disruptions in metabolites tied to SCFA synthesis and inflammation pathways, and integrated analysis found significant correlations between taxa such as Blautia, Butyricicoccus, Coprococcus, Ruminococcus, Bacteroides, and Clostridium and plasma metabolites including alpha-benzylbutyric acid, acetic acid, and succinic acid.

What are the greatest implications of this study?

The findings suggest that gut microbiota dysbiosis and consequent metabolic dysfunction, particularly reduced SCFA production, may play a role in LNTB pathophysiology. Because SCFAs and related anti-inflammatory commensal bacteria appear diminished in LNTB, restoring these microbial functions could represent a novel therapeutic target for disease management. This work opens a new avenue for considering the gut-immune axis in tuberculosis affecting lymph nodes, beyond the traditional focus on pulmonary disease.

What was studied?

The human microbiome plays a pivotal role in pancreatic cancer (PC). This study investigates the abundance of specific gut and oral microbes in PC patients compared to healthy controls.

Who was studied?

A cohort of 20 diagnosed PC patients and an equivalent control group were recruited. Comprehensive lifestyle data, such as overall food consumption, were collected. Saliva and stool samples were prepared. Microbial DNA was extracted from stool and saliva samples using specialized kits. Primers were designed targeting the conserved regions of the 16 S rRNA genes from Neisseria elongata, Granulicatella adiacens, Fusobacterium nucleatum, Roseburia intestinalis, and Bifidobacterium bifidum. The quantities of selected bacterial species were evaluated using real-time quantitative PCR.

What were the most important findings?

Granulicatella adiacens and Fusobacterium nucleatum were significantly increased in the PC group (medians: 7.35 and 4.37 log10 CFU/g, respectively) compared to controls (medians: 2.43 and 1.20 log10 CFU/g ; P < 0.001 for both). Conversely, Neisseria elongata, Roseburia intestinalis, and Bifidobacterium bifidum levels were significantly lower in PC patients (medians: 2.37, 2.34, and 3.45 log10 CFU/g, respectively) compared to controls (medians: 5.63, 5.07, and 4.34 log10 CFU/g; P < 0.001). The principal component analysis confirmed distinct clustering of microbiota profiles between the two groups, with key microorganisms associated with PC. The discriminatory performance of clinical and microbiota variables demonstrated notable accuracy in classifying PC, particularly metrics such as hemoglobin and hematocrit, achieving an area under the curve (AUC) of 1.00.

What are the greatest implications of this study?

In summary, these findings highlight the significant association between microbiome composition and PC, underscoring the potential of microbiota profiles as non-invasive diagnostic biomarkers that warrant further investigation for early detection and therapeutic targeting in clinical practice.

What was studied?

This study investigated how type 2 diabetes mellitus (T2DM) affects the vaginal microbiota in perimenopausal and postmenopausal women. Researchers used metagenomic sequencing of vaginal secretion samples to characterize microbial community structure and functional homeostasis. They assessed alpha diversity (Observe, ACE, Shannon-Weaver, Gini-Simpson indices) and beta diversity (PCoA, NMDS), and applied taxonomic profiling, LEfSe analysis, co-occurrence network construction, and neutral community modeling to determine whether stochastic or deterministic processes shaped the community.

Who was studied?

The study included 22 women with T2DM (the DM group) and 23 healthy women (the CT group), all in perimenopausal or postmenopausal life stages. The two groups did not differ significantly in age (62.22 plus or minus 5.74 years vs. 58.23 plus or minus 7.55 years, p = 0.052) or in the proportion of perimenopausal versus postmenopausal participants (3/19 vs. 5/18, p = 0.748). This design allowed the researchers to isolate the effect of T2DM on the vaginal microbiota independent of age or menopausal status.

What were the most important findings?

The DM group showed significantly higher alpha diversity than the control group (p < 0.05), along with distinct clustering on beta diversity analysis (p < 0.05). This shift was marked by reduced Lactobacillus abundance in the diabetic women compared to healthy controls. The abstract indicates additional taxonomic and network-level differences were identified through LEfSe and co-occurrence analyses, alongside evidence bearing on stochastic versus deterministic community assembly, though the abstract text provided does not detail every specific taxon or network finding beyond the Lactobacillus reduction.

What are the greatest implications of this study?

The findings suggest that T2DM is associated with a less Lactobacillus-dominated, more diverse and heterogeneous vaginal microbial community in perimenopausal and postmenopausal women, independent of age or menopausal stage. Since a Lactobacillus-depleted vaginal environment is generally linked to reduced protective function, this points to T2DM as a distinct driver of vaginal dysbiosis risk in this population. These results underscore the need to consider metabolic status, not just menopause, when evaluating vaginal microbiome health and potential dysbiosis-adjustment strategies in aging women.

What was studied?

This randomized, placebo-controlled trial examined whether resistant starch (RS), a prebiotic, has therapeutic effects in metabolic dysfunction-associated steatotic liver disease (MASLD). The researchers focused on why RS efficacy was heterogeneous, since about 30% of participants showed limited benefit. Using multi-omics analysis, fecal microbiota transplantation, population stratification, network analysis, and in vitro and in vivo experiments, they sought the microbial basis of this variable response. They then built a predictive model combining baseline microbial and clinical features to forecast who would respond.

Who was studied?

Participants were drawn from the original randomized, placebo-controlled trial of resistant starch in MASLD, with the finding of heterogeneous response replicated in a separate multi-center trial (ChiCTR2300074588). The abstract does not give exact participant numbers or demographic details for either trial. A strain, Bifidobacterium pseudocatenulatum RRP01, was isolated from the study cohort for further experimentation.

What were the most important findings?

Baseline gut microbiota composition was the dominant contributor to whether a participant responded to resistant starch. Prevotella was identified as a key cause of low response because it inhibits RS-degrading bacteria, impairing RS utilization. In contrast, the cohort-derived strain Bifidobacterium pseudocatenulatum RRP01 restored RS degradation and improved the RS response that Prevotella had attenuated. A predictive model integrating baseline microbial and clinical features achieved an area under the curve of 0.74 to 0.87 for stratifying likely responders.

What are the greatest implications of this study?

The findings show that pre-existing gut microbiota composition, not just the intervention itself, determines whether resistant starch benefits patients with MASLD. This supports moving toward microbiota-oriented precision therapeutics, where baseline microbial and clinical features are used to predict who will respond before treatment begins. It also points to specific microbiota-targeted strategies, such as supplementing Bifidobacterium pseudocatenulatum RRP01, to overcome Prevotella-driven non-response and expand the benefit of prebiotic therapy to more patients.

What was studied?

This study aimed to investigate the differences in gut microbiota composition and diversity among healthy controls (HC) and patients with colorectal lesions-including common colorectal polyps, small colorectal adenomas (SCRA), large colorectal adenomas (LCRA), and intramucosal carcinoma (IMC)-to identify bacterial species associated with disease progression and provide novel insights into the diagnosis and treatment of CRC based on the "polyp-adenoma-carcinoma" sequence.

Who was studied?

A total of 250 participants were recruited from the First Affiliated Hospital of Anhui Medical University between July 2023 and June 2024. The cohort included 30 HC, 52 with common colorectal polyps, 58 with SCRA, 56 with LCRA, and 54 with IMC. Fecal samples were collected for bacterial DNA extraction, followed by metagenomic sequencing to analyze microbial diversity. Differential microbiota analysis was performed using the R package microbiomeMarker and LEfSe. Group classification and feature identification were conducted using a random forest model. Functional profiling was performed using DIAMOND against the KEGG and MetaCyc databases.

What were the most important findings?

No significant differences in α-diversity were observed across the groups. β-diversity analysis revealed significant differences in Bray-Curtis and Jaccard distances among the groups. The composition and abundance of gut microbiota at the phylum, class, order, family, genus, and species levels were significantly altered. LEfSe analysis identified specific bacterial species with significant differences in IMC compared to other groups. Furthermore, the random forest model effectively distinguished patients with IMC from other groups based on distinct microbial signatures. Functional profiling revealed that the gut microbiota undergoes metabolic reprogramming from a homeostatic to a pro-tumorigenic phenotype during CRC progression as well as reduced protective pathway abundance and impaired energy/biosynthetic metabolism in CRC-associated microbiota.

What are the greatest implications of this study?

Gut microbiota profiles varied significantly among HC, polyp, SCRA, LCRA, and IMC groups. Specific microbial signatures were able to effectively differentiate IMC from both HC and non-malignant colorectal lesions, highlighting their potential as diagnostic biomarkers.

What was studied?

This study examined the relationship between the gut microbiome and the host genome and transcriptome in colorectal cancer (CRC). Researchers profiled the fecal microbiome structure alongside genomic and transcriptomic data from matched tumor and normal mucosa tissue. Exome sequencing was used to identify somatic mutations, and gene expression patterns were annotated and clustered against microbial abundance data. Immune and stromal cell composition was also estimated from the transcriptomic profiles.

Who was studied?

The cohort consisted of 41 patients with colorectal cancer. For each patient, matched tumor tissue and normal mucosa tissue were analyzed alongside fecal microbiome samples. The abstract does not provide further demographic details such as age, sex, or geographic origin of the participants.

What were the most important findings?

The researchers identified 22 gut microbial species significantly associated with CRC and estimated relative abundance across functional (KEGG) pathway categories. Four significantly mutated genes, TP53, APC, KRAS, and SMAD4, were linked to specific cancer-associated microbes. Fusobacterium nucleatum in particular showed a positive correlation with multiple host metabolic pathways, tying a specific pathogen to altered tumor metabolism. The abstract text is truncated before further results are described.

What are the greatest implications of this study?

The findings support a functional link between specific gut bacteria, such as Fusobacterium nucleatum, and the somatic mutation landscape and metabolic activity of colorectal tumors. This multi-omic approach suggests that microbial taxa may interact with host driver mutations like TP53, APC, KRAS, and SMAD4 rather than merely coexisting with the tumor. Such associations could inform future work on microbiome-informed risk stratification or targets in CRC, though the abstract does not describe therapeutic testing or outcomes.

What was studied?

This study examined gut microbial features associated with Parkinson's disease (PD) by meta-analyzing shotgun metagenomic sequencing data across six independent datasets from different countries. The researchers also established GC-MS and LC-MS/MS assays to directly quantify fecal short-chain fatty acids (SCFAs) and fecal polyamines. They analyzed taxonomic composition, functional gene pathways, and carbohydrate-active enzymes (CAZymes) in relation to PD status, adjusting for confounding factors.

Who was studied?

The core dataset consisted of 94 PD patients and 73 controls whose fecal samples were shotgun sequenced in Japan. This Japanese cohort was combined with five previously reported datasets from the USA, Germany, China (two separate cohorts), and Taiwan. In total, the meta-analysis spanned six countries, giving the study an international, multi-cohort scope rather than a single-population sample.

What were the most important findings?

Across all six datasets, alpha-diversity was consistently increased in PD. Taxonomic analysis showed Akkermansia muciniphila was increased in PD, while Roseburia intestinalis and Faecalibacterium prausnitzii, both associated with anti-inflammatory, butyrate-related commensal activity, were decreased. Genes for riboflavin and biotin biosynthesis and five of six CAZyme categories were markedly decreased in PD, and fecal SCFAs and polyamines were significantly reduced, with riboflavin/biotin gene abundance positively correlated with these metabolite levels.

What are the greatest implications of this study?

The convergent, cross-country decrease in Faecalibacterium prausnitzii, Roseburia intestinalis, SCFAs, and polyamines suggests a reproducible loss of beneficial, anti-inflammatory commensal function in PD gut microbiota. Because the specific bacteria driving reduced riboflavin biosynthesis differed between Japan/USA/Germany and China1/China2/Taiwan, the findings imply that shared functional deficits in PD can arise from different taxonomic routes depending on population. This points toward B-vitamin biosynthesis and short-chain fatty acid/polyamine metabolism as potential functional biomarkers or intervention targets for PD that generalize better across populations than single-taxon signatures.

What was studied?

This study examined the gut microbiome's association with type 2 diabetes (T2D) by analyzing shotgun metagenomic sequencing data. Researchers looked beyond species-level associations to strain-level and phylogenetic diversity within species, aiming to identify specific microbial features and functional pathways linked to T2D. The analysis also explored community-level functional changes, such as perturbations in glucose metabolism, and mechanisms like horizontal gene transfer that could explain strain-specific effects on metabolic risk.

Who was studied?

The study drew on 8,117 shotgun metagenomes pooled from 10 cohorts spanning the United States, Europe, Israel, and China. These cohorts included individuals with type 2 diabetes, prediabetes, and normoglycemic (non-diabetic) status. The abstract does not provide individual-level demographic details, but the analysis represents a large, multi-national, cross-cohort metagenomic dataset.

What were the most important findings?

Dysbiosis in 19 phylogenetically diverse species was associated with T2D at a false discovery rate below 0.10, including enrichment of Clostridium bolteae and depletion of Butyrivibrio crossotus. These microorganisms contributed to community-level functional changes, such as perturbations in glucose metabolism, that may underlie T2D pathogenesis. The study further identified within-species phylogenetic diversity across 27 species, such as Eubacterium rectale, that explained inter-individual differences in T2D risk, with some effects attributable to strain-specific gene carriage involved in horizontal gene transfer and other novel biological processes.

What are the greatest implications of this study?

By resolving microbial associations with T2D down to the strain level, this work helps explain why prior species-level findings have been inconsistent across studies. Identifying strain-specific gene carriage and functional pathways, including those affecting glucose metabolism, offers a clearer mechanistic basis for how gut microbes may contribute to T2D pathogenesis. This strain-resolved approach could inform future efforts to develop microbiome-based biomarkers or targeted interventions for metabolic disease risk.

What was studied?

This study examined how environmental, socioeconomic, and health factors relate to gut microbiome composition at both the species and strain level. Researchers used deeply sequenced metagenomic data to identify associations between bacterial species and a range of host phenotypes and situational factors. They also performed a meta-analysis of species-level profiles across multiple datasets to look for consistent patterns, such as links to body mass index.

Who was studied?

The study drew on a community-based cohort of 1,871 people living in 19 isolated villages in the Mesoamerican highlands of western Honduras. This is a non-industrialized, geographically isolated population, a setting the authors note remains uncommon in deep gut microbiome sequencing studies. Additional comparisons were made using species-level profiles from other, unspecified datasets as part of a meta-analysis.

What were the most important findings?

Socioeconomic factors accounted for 51.44% of all associations found between the gut microbiome and human phenotypes, making them the dominant category of influence. Meta-analysis across datasets identified several bacterial species associated with body mass index, consistent with prior research. Incorporating strain-level phylogenetic information changed the overall picture of host-microbiome relationships, especially for factors like household wealth, where wealthier individuals were found to harbor different strains of Eubacterium rectale than less wealthy individuals.

What are the greatest implications of this study?

The findings suggest that socioeconomic circumstances are a major driver of gut microbiome variation, potentially more so than many other individual health factors. The demonstration that strain-level differences (not just species presence) track with wealth indicates that species-level analysis alone can miss biologically meaningful variation. The authors conclude that gut microbiome surveillance in such populations could help illuminate broader patterns relevant to both individual and public health.

What was studied?

This study used whole-genome shotgun sequencing and gas chromatography/mass spectrometry to profile gut microbial and metabolic signatures across seven different malignancies. The researchers compared taxonomic and metabolomic configurations in cancer patients against sex- and age-matched healthy controls. The goal was to identify both common and cancer-type-specific gut microbiome and metabolite alterations.

Who was studied?

The study included patients with colorectal cancer (40), stomach cancer (45), breast cancer (71), lung cancer (34), melanoma (50), lymphoid neoplasms (60), and acute myeloid leukemia (40). Each cancer group was compared against its own sex- and age-matched healthy control group. In total the analysis spanned 300 cancer patients across seven malignancy types plus their matched controls.

What were the most important findings?

Beta-diversity differed between every cancer group and its healthy controls, while alpha-diversity differed only for the lymphoid neoplasm and acute myeloid leukemia groups. Of 203 unique species identified, 179 were under-represented and 24 were over-represented in cancer patients relative to controls. Faecalibacillus intestinalis was under-represented across all seven cancer groups, and Anaerostipes hadrus was under-represented in all groups except stomach cancer, with a marked reduction in the gut microbiome cancer index in every group except acute myeloid leukemia. Among the short-chain fatty acids and amino acids tested, formic acid concentration was significantly altered.

What are the greatest implications of this study?

The consistent depletion of Faecalibacillus intestinalis and altered formic acid levels across seven distinct cancer types suggest these may represent shared, cross-cancer markers of gut dysbiosis rather than disease-specific findings. This points toward a common gut microbial and metabolic signature that could inform future pan-cancer diagnostic or monitoring approaches. Because the pattern held despite differences in cancer biology and location, it strengthens the case for a generalizable link between gut dysbiosis and malignancy.

What was studied?

This study used metagenomic sequencing to characterize taxonomic and functional changes in the gut microbiome of people with Parkinson's disease (PD). The researchers examined how these microbial changes relate to bacterial metabolites and to clinical disease progression. Motor and non-motor symptoms were tracked over up to five yearly study visits using the MDS-UPDRS scale and levodopa equivalent dose. Stool samples collected at baseline were used for the metagenomic analysis.

Who was studied?

The study population consisted of 176 individuals with Parkinson's disease and 100 control participants who provided baseline stool samples for metagenomic sequencing. Disease progression was followed longitudinally across as many as five yearly visits using standardized clinical rating scales. The abstract does not specify age, sex distribution, or geographic recruitment site for these participants.

What were the most important findings?

PD-derived stool samples showed reduced intermicrobial connectivity and seven species that were differentially abundant compared to controls. A range of bacterial functions also differed between groups, including depletion of carbohydrate degradation pathways and enrichment of ribosomal genes. Notably, Faecalibacterium prausnitzii-specific reads contributed to more than half of all the differentially abundant functional terms identified. A subset of these disease-associated functional terms correlated with faster progression on MDS-UPDRS part IV and could distinguish slow from fast progressors with moderate accuracy.

What are the greatest implications of this study?

The findings reinforce that Parkinson's disease involves large-scale, functional disruption of the gut microbiome, not just shifts in a handful of taxa. The outsized contribution of Faecalibacterium prausnitzii, a key butyrate-producing, anti-inflammatory commensal, to the disrupted functional signature suggests its depletion may be mechanistically important rather than incidental. The link between specific functional terms and faster motor progression raises the possibility that gut microbial function could serve as a biomarker of disease trajectory. These results support further investigation into F. prausnitzii and related carbohydrate-degradation pathways as targets for monitoring or intervention in PD.

What was studied?

This study used deep shotgun metagenomic sequencing to characterize the taxonomic and functional composition of the gut microbiome in older adults from Singapore. The researchers examined how gut microbial communities and their metabolic capabilities relate to aging phenotypes. They performed joint species-level analysis together with other Asian cohorts to identify age-associated shifts in microbial composition and function. The work also linked microbiome features to clinical markers of inflammation, cardiometabolic health, and liver health.

Who was studied?

The cohort consisted of 234 community-living octogenarians in Singapore who were described as well-phenotyped. Their gut microbiomes were compared jointly against data from other Asian cohorts to identify consistent age-associated species shifts. The abstract does not specify sex distribution, exact age range beyond octogenarian status, or additional demographic details.

What were the most important findings?

Aging was associated with reduced microbial richness and enrichment of specific Alistipes and Bacteroides species, including Alistipes shahii and Bacteroides xylanisolvens. Functional analysis showed a corresponding expansion of metabolic potential toward pathways synthesizing and utilizing amino-acid precursors, in contrast to the dominant butyrate-producing guilds such as Faecalibacterium prausnitzii and Roseburia inulinivorans that generate butyrate from pyruvate. The study also identified more than ten robust microbial associations with inflammation and with cardiometabolic and liver health markers, including a potential probiotic species, Parabacteroides goldsteinii.

What are the greatest implications of this study?

The findings suggest that healthy aging in this population is accompanied by a measurable shift away from butyrate-producing commensals like Faecalibacterium prausnitzii toward microbes with alternate amino-acid metabolic capacity. This shift, combined with the identified links to inflammation and cardiometabolic and liver health markers, points to specific microbial species and pathways that could serve as biomarkers or targets for supporting healthy aging. The results also highlight potential probiotic candidates, such as Parabacteroides goldsteinii, for further investigation in aging-related interventions.

What was studied?

This study examined how gut microbiota and their metabolites change during acute pancreatitis (AP), an inflammatory disease of the pancreas that currently lacks effective therapy. The researchers used metagenomic sequencing to profile gut bacterial communities and metabolomic sequencing to profile metabolites, then applied correlation analysis to clarify how the two systems interact. KEGG pathway analysis was used to connect differential bacteria and metabolites to specific metabolic functions.

Who was studied?

The study was conducted using three distinct AP mouse models rather than human subjects. Each model was constructed specifically to allow comparison of gut microbiota and metabolite profiles across different disease conditions. No human cohort, sample size, or patient population is described in the abstract.

What were the most important findings?

Each AP mouse model exhibited a unique flora and metabolite profile, with differential bacteria and metabolite-enriched pathways correlating with lipid metabolism and amino acid metabolism. Two bacterial species, Burkholderiales bacterium YL45 and Bifidobacterium pseudolongum, emerged as core differential species across the models. Eleven differential metabolites were also identified as appearing to exert effects during the course of AP.

What are the greatest implications of this study?

By mapping the crosstalk between gut microbiota and their derived metabolites, the study suggests specific bacterial species and metabolites, especially those tied to lipid and amino acid metabolism, may play mechanistic roles in AP development. This integrated metagenomic-metabolomic approach could inform new diagnostic markers and treatment strategies for AP. Further exploration of this microbiota-metabolite relationship is proposed as a route to novel clinical insights.

What was studied?

This study used metagenomic sequencing to examine how chemotherapy affects the gut microbiota and antibiotic resistance genes (ARGs) in patients with acute leukemia (AL). Researchers compared stool samples collected before and after chemotherapy to track shifts in microbial composition and resistance gene carriage. The analysis also explored how antibiotic dosage shapes microbiota and ARG networks, and how gut microbial species relate to circulating inflammatory markers.

Who was studied?

The subjects were patients diagnosed with acute leukemia who provided stool samples both before and after undergoing chemotherapy. The abstract does not give an exact number of patients, so the precise cohort size cannot be stated. Blood samples from these same patients were also analyzed for inflammatory biomarkers alongside the paired stool metagenomes.

What were the most important findings?

Post-chemotherapy stool samples showed decreased alpha diversity and greater sample-to-sample dispersion compared with pre-chemotherapy samples, along with shifts in the abundance of specific bacterial taxa. Enterococcus, Klebsiella, and Escherichia coli were identified as the most prevalent carriers of antibiotic resistance genes. Correlation analysis linked specific microbial species to inflammatory markers, including C-reactive protein (CRP) and adenosine deaminase (ADA), and co-occurrence networks connected 179 microbial and ARG nodes across 206 edges. Treatment with cephamycin and sulfonamide antibiotics was associated with the emergence of multidrug-resistant Klebsiella colonization.

What are the greatest implications of this study?

The findings suggest that chemotherapy in acute leukemia patients disrupts gut microbial balance in ways that favor colonization by resistant, potentially pathogenic Enterobacteriaceae members such as Klebsiella and E. coli. The observed links between specific antibiotics, resistant bacteria, and inflammatory biomarkers highlight the need for careful antibiotic selection and dosing during leukemia treatment to limit multidrug-resistant colonization. These data support closer monitoring of gut microbiota and ARG dynamics as a tool for anticipating infection risk and inflammatory complications in immunocompromised leukemia patients.

What was studied?

This study investigated the neonatal gut bacterial and viral microbiome in infants exposed to HIV but who remained uninfected, and examined how this exposure relates to inflammatory biomarkers in plasma. The researchers also tested whether HIV exposure alters antibody-microbiota binding in the neonatal gut. Finally, they assessed whether antibodies present in breast milk affect the growth of commensal gut bacteria.

Who was studied?

The study compared neonates exposed to HIV but uninfected (nHEU) with unexposed, uninfected neonates (nHU). Breast milk from mothers living with HIV was also analyzed and compared for its antibody function. The abstract does not give specific sample sizes, so the exact cohort size cannot be stated.

What were the most important findings?

Neonates exposed to HIV but uninfected showed an altered gut bacteriome and a milder change in the enteric DNA virome compared to unexposed neonates. HIV exposure also differentially affected IgA binding to gut microbiota. The relative abundance of Blautia spp., in both whole stool and IgA-bound microbiota, was positively associated with plasma C-reactive protein levels. Breast milk IgA from mothers living with HIV showed a significantly reduced ability to inhibit the growth of Blautia coccoides, and this reduced inhibitory capacity was associated with inflammation in the exposed neonates.

What are the greatest implications of this study?

The findings suggest that elevated inflammation in HIV-exposed but uninfected neonates may stem in part from a weakened capacity of maternal breast milk IgA to control specific commensal bacteria such as Blautia coccoides. This points to a potential antibody-mediated mechanism linking maternal HIV status, infant gut microbiota composition, and systemic inflammation in the infant. Understanding this pathway could inform strategies to support healthy immune development in this vulnerable population.

What was studied?

This study examined whether gut microbiome composition differs in people with nontreated plaque psoriasis compared with people without the condition. The researchers used metagenomic gene sequencing of fecal samples to compare microbial taxa and functional gene pathways across groups. They also compared psoriasis patients directly against their own healthy spouses, a design meant to control for shared household and dietary exposures. Gene functional analysis was performed to see whether specific microbial pathways were altered alongside compositional shifts.

Who was studied?

The study included 32 nontreated plaque psoriasis patients, 15 unrelated healthy controls, and 17 healthy spouses of the patients (healthy couples). Fecal samples from these three cohorts were analyzed by metagenomic sequencing. The abstract does not specify age, sex distribution, or geographic origin of participants.

What were the most important findings?

The relative abundance of intestinal microbiota in the psoriasis group differed from both healthy controls and the patients' own healthy partners, though overall microbial diversity was similar across all three groups. At the phylum level, the relative abundances of Firmicutes and Bacteroidetes were reversed in psoriasis patients, and Escherichia coli was significantly enriched compared with both comparison groups. Functional gene analysis showed ribosome pathway genes upregulated, while flagellar assembly and bacterial chemotaxis pathways were downregulated in the psoriasis cohort. Additionally, microbiota composition differed between patients with severe psoriasis and those with milder disease, suggesting a relationship between gut dysbiosis and disease severity.

What are the greatest implications of this study?

These findings strengthen the case for a link between intestinal flora and psoriasis, including a possible relationship between microbial dysbiosis and disease severity. Using patients' own healthy spouses as a comparison group helps address some of the conflicting results in prior psoriasis microbiome research. The authors note that further, more meaningful experiments are needed to clarify the mechanisms underlying this association.

What was studied?

This study investigated the role of gut microbiota and their metabolites, particularly short-chain fatty acids (SCFAs), in the pathogenesis of functional constipation (FC). The researchers used shotgun metagenomic sequencing of gut microbiota alongside serum SCFA analysis to examine relationships between microbial composition, butyric acid levels, and defecation frequency. They then tested the direct effects of butyrate on intestinal neurons using an in vitro mouse model to explore a possible mechanistic link between microbial butyrate metabolism and enteric nervous system damage.

Who was studied?

The primary cohort consisted of 460 Chinese women with differing defecation frequencies, who underwent shotgun metagenomic sequencing and serum SCFA measurement. Findings were verified in an independent cohort of 6 patients with functional constipation and 6 controls. In addition, mouse intestinal neurons were used in vitro to test the cellular effects of butyrate exposure at concentrations of 0.1, 0.5, 1, and 2.5 mM.

What were the most important findings?

The abundance of Fusobacterium varium, a butyric acid-producing bacterium, was positively correlated with defecation frequency, while serum butyric acid concentration was negatively correlated with defecation frequency. These findings were confirmed in the independent validation cohort. In vitro, intestinal neurons treated with 0.5 mM butyrate proliferated better than neurons exposed to other tested concentrations, with significant differences observed in cell cycle and oxidative phosphorylation signaling pathways.

What are the greatest implications of this study?

The findings suggest that abnormal butyrate metabolism, including altered production by gut bacteria such as Fusobacterium varium and shifts in serum butyrate levels, may damage the enteric nervous system and contribute to functional constipation. This points to butyrate-modulating microbes and serum butyrate concentration as potential biomarkers or targets for understanding and managing FC. It also highlights that butyrate's effect on enteric neurons is concentration-dependent, meaning both insufficient and excessive levels may be relevant to disease mechanisms.

What was studied?

This study examined the gut microbiota landscape of patients with diffuse large B-cell lymphoma (DLBCL) and its relationship to peripheral blood immune cell subtypes. Researchers used metagenomic sequencing to characterize gut bacterial composition and full-spectral flow cytometry to profile immune cell subsets. The goal was to identify microbiota and immune features that differ across NCCN-International Prognostic Index (NCCN-IPI) risk categories, since the gut microbe landscape in DLBCL and its link to immunity had remained largely unknown.

Who was studied?

A total of 87 newly diagnosed adult DLBCL patients were enrolled and had peripheral blood samples collected for immune cell subtyping. Of these, 69 of the 87 patients also had stool or tumor-associated samples submitted for metagenomic sequencing to assess microbiota composition. Patients were grouped according to NCCN-IPI risk categories: low-risk, low-intermediate-risk, intermediate-high-risk, and high-risk.

What were the most important findings?

Metagenomic sequencing identified 10 bacterial phyla, 31 orders, and 455 bacterial species across the 69 profiled DLBCL patients. Six bacteria showed abundance differences of note, including Blautia sp. CAG 257, Actinomyces sp. S6 Spd3, Streptococcus parasanguinis, Bacteroides salyersiae, and Enterococcus faecalis. The abstract does not mention Bacteroides fragilis, polysaccharide A, or the B. fragilis toxin, so this study's findings center on other bacterial taxa and their association with NCCN-IPI risk groups and peripheral immune cell subsets.

What are the greatest implications of this study?

By linking specific gut bacterial abundances to NCCN-IPI prognostic risk groups and peripheral immune cell subtypes, this work suggests the gut microbiome may play a role in shaping immune status and disease risk stratification in DLBCL. These integrated microbiome-immune signatures could eventually inform prognostic tools or risk-adapted monitoring for newly diagnosed patients. Further validation would be needed before such microbiota features could guide clinical decision-making in lymphoma care.

What was studied?

This study examined the gut microbiome in Parkinson's disease (PD) using shotgun metagenomic sequencing, a method that captures microbial functional potential rather than taxonomy alone. The researchers designed a nested case-control study to investigate both recently onset PD and prodromal (premotor) PD, a stage that prior microbiome research had largely overlooked. They analyzed fecal metagenomes to identify bacterial species and metabolic pathways associated with PD and with features suggestive of the prodromal phase.

Who was studied?

The study drew on 420 participants nested within two large epidemiological cohorts, the Nurses' Health Study and the Health Professionals Follow-up Study. This included 75 people with recently onset PD, 101 with features of prodromal PD, 113 controls with constipation, and 131 healthy controls. The design allowed comparison across a spectrum from prodromal symptoms through diagnosed disease against two distinct control groups.

What were the most important findings?

Participants with PD or features of prodromal PD showed depletion of several strict anaerobes, bacteria types that the abstract links to reduced inflammation. A microbiome-based classifier achieved moderate accuracy in distinguishing recently onset PD cases from controls, with an area under the curve of 0.76 based on species composition and 0.74 based on functional pathways. These taxonomic changes were accompanied by corresponding functional shifts in the metagenome, indicating that both which microbes are present and what they metabolically do differ in PD.

What are the greatest implications of this study?

By identifying microbial changes already present in prodromal, premotor PD, this study suggests gut microbiome alterations may precede or accompany the earliest detectable stages of disease rather than only appearing after motor symptoms emerge. The depletion of anaerobes associated with reduced inflammation points toward loss of anti-inflammatory microbial function as a feature of the disease process. The moderate classifier accuracy suggests gut metagenomic profiles could eventually contribute to tools for identifying at-risk individuals, though the abstract does not claim diagnostic readiness.

What was studied?

This study investigated the duodenal mucosa-associated microbiota and its surrounding microenvironment in relation to hyperglycemia, an area far less studied than stool microbiota in metabolic disease. The researchers compared paired stool and duodenal microbial samples between hyperglycemic and normoglycemic individuals. They also assessed the duodenal microenvironment directly by measuring tissue oxygen saturation, serum inflammatory markers, and zonulin as a marker of gut permeability. The goal was to determine whether duodenal, rather than stool, microbial changes track more closely with glycemic status.

Who was studied?

The study population consisted of 33 subjects with hyperglycemia, defined as HbA1c of 5.7% or higher and fasting plasma glucose above 100 mg/dl, compared against 21 normoglycemic subjects. Both groups contributed paired stool and duodenal samples, allowing direct comparison of microbiota across two body sites within the same individuals. No further demographic details are given in the abstract.

What were the most important findings?

Hyperglycemic subjects had a significantly higher duodenal bacterial count than normoglycemic subjects, along with increased pathobionts and reduced beneficial flora. This bacterial overload correlated with elevated serum zonulin and higher TNF-alpha, suggesting a link to increased gut permeability and inflammation. The hyperglycemic group also showed reduced duodenal oxygen saturation, higher total leukocyte count, and lower IL-10, indicating a systemic proinflammatory state. Notably, unlike stool flora, duodenal bacterial profile variability was specifically associated with glycemic status.

What are the greatest implications of this study?

These findings suggest the duodenal microbiome and its local microenvironment, rather than stool alone, may play a distinct role in the pathogenesis of hyperglycemia and prediabetes. The association between bacterial overload, reduced oxygen saturation, and systemic inflammatory markers points to a possible mechanistic pathway linking small intestinal dysbiosis to metabolic dysfunction. This work highlights the duodenum as an underexplored but potentially important site for understanding and possibly intervening in early glycemic disturbances.

What was studied?

This study examined whether gut microbial communities are linked to the severity of COVID-19 in hospitalized patients. Researchers profiled stool samples using metagenomic sequencing to identify gut microbial taxa, their biochemical pathways, and stool metabolites associated with disease severity. They also built a random forest classifier to test whether microbiome data could distinguish severe from moderate COVID-19, and used network analyses to examine microbial community structure.

Who was studied?

The study included 127 hospitalized patients with COVID-19, of whom 79 had severe disease and 48 had moderate disease. These patients collectively provided 241 stool samples collected from April 2020 to May 2021. The classifier's performance was also externally validated in an independent cohort, though details of that cohort are not given in the abstract.

What were the most important findings?

Forty-eight microbial species were associated with severe COVID-19 after accounting for antibiotic use, age, sex, and comorbidities. Severe disease was marked by significant in-hospital depletion of Fusicatenibacter saccharivorans and Roseburia hominis, two commensals previously linked to post-acute COVID syndrome, or long COVID, suggesting they may serve as early biomarkers for its later development. The random forest classifier achieved excellent performance distinguishing severe from moderate COVID-19 stool samples, a result that held up in external validation, and network analysis pointed to fragility in the gut microbial community structure of severe cases.

What are the greatest implications of this study?

The findings suggest that gut microbial depletion during acute COVID-19, particularly of Fusicatenibacter saccharivorans and Roseburia hominis, could help identify patients at risk of developing long COVID before it manifests. The strong, externally validated classifier performance indicates that stool-based microbiome signatures could become a practical tool for stratifying COVID-19 severity risk. These results also reinforce the broader role of specific gut commensals in shaping immune resilience during respiratory viral infection.

What was studied?

The role of the microbiota-gut-brain axis in Parkinson's disease (PD) has received increasing attention. Although gender differences are known to an essential role in the epidemiology and clinical course of PD, there are no studies on the sex specificity of the microbiota-gut-brain axis in the development and progression of PD.

Who was studied?

Fresh fecal samples from 24 PD patients (13 males, 11 females) were collected for metagenomic sequencing. The composition and function of the gut microbiota were analyzed by resting-state functional magnetic resonance imaging (fMRI). Gender-dependent differences in brain ALFF values and their correlation with microbiota were further analyzed.

What were the most important findings?

The relative abundance of Propionivibrio, Thermosediminibacter, and Flavobacteriaceae_noname was increased in male PD patients. LEfse analysis showed that Verrucomicrobial, Akkermansiaceae, and Akkermansia were dominant in the males. In female patients, the relative abundance of Propionicicella was decreased and Escherichia, Escherichia_coli, and Lachnospiraceae were predominant. The expression of the sesquiterpenoid and triterpenoid biosynthesis pathways was increased in male PD patients and was statistically different from females. Compared to the Male PD patients, female patients showed decreased ALFF values in the left inferior parietal regions, and the relative abundance of Propionivibrio was positively correlated with the regional ALFF values.

What are the greatest implications of this study?

Our study provides novel clinical evidence of the gender-specific relationship between gut microbiota alterations and brain function in PD patients, highlighting the critical role of the microbiota-gut-brain axis in gender differences in PD.

What was studied?

This study examined how the gut microbiota changes with age and how those age-related changes relate to colorectal cancer (CRC). The researchers analyzed 11 metagenomic data sets, correcting for batch effects, then compared species composition and abundance across three age groups in both healthy individuals and CRC samples. They used LEfSe analysis to identify bacteria whose relative abundance differed by age group, then built age-prediction and CRC-risk-prediction models from those age-differentiated species.

Who was studied?

The abstract does not report a single original cohort with a specific sample size. Instead, the study population consisted of previously published metagenomic samples drawn from 11 combined data sets accessed through the curatedMetagenomicData R package, covering both healthy individuals and people with colorectal cancer. These samples were stratified into three age groups for comparison.

What were the most important findings?

The structure and composition of the gut microbiota differed significantly across the three age groups in both healthy and CRC samples. Bacteroides vulgatus abundance was lower in the older group compared to the other two groups, while Bacteroides fragilis abundance increased with aging. The researchers also identified seven bacterial species whose abundance rose with age, and found that abundance of pathogenic bacteria, including Escherichia coli, increased as well.

What are the greatest implications of this study?

By linking specific age-associated shifts in gut microbiota, such as declining Bacteroides vulgatus and rising Bacteroides fragilis and Escherichia coli, to both healthy aging and CRC samples, this work suggests the microbiome could serve as a biomarker for biological aging and CRC risk. The construction of age-prediction and CRC-risk-prediction models based on these age-differentiated bacteria points toward potential microbiota-based tools for estimating cancer risk as people age. This approach could inform future screening or risk-stratification strategies that account for age-related microbial changes.

What was studied?

This pilot study explored the composition of the gut microbiota in patients with prediabetes and in treatment naive type 2 diabetes (T2D), compared to healthy subjects. Fecal samples were analyzed using the bacterial 16S rRNA gene, with two complementary technologies employed to give broad coverage of potential T2D associated bacteria: the GA-map 131-plex probe panel spanning the V3-V9 regions, and the LUMI-Seq full-length 16S sequencing platform spanning V1-V9. The researchers used multivariate methods to explore variation between groups, estimated differential bacterial abundance, and built classification models to identify microbiota signatures that could discriminate between the groups.

Who was studied?

The study included 24 patients with prediabetes and 18 patients with treatment naive type 2 diabetes, recruited alongside healthy comparison subjects in Norway. Fecal samples were collected from all participants for bacterial genomic DNA extraction and analysis. The abstract does not provide further demographic details such as age or sex distribution.

What were the most important findings?

Using two independent 16S rRNA based technologies, the study found variation in gut microbiota composition across the prediabetes, treatment naive T2D, and healthy groups. Differential bacterial abundance was estimated between groups, and classification models were used to identify microbiota signatures capable of discriminating prediabetes and T2D patients from healthy subjects. The abstract does not specify which individual taxa, including Faecalibacterium prausnitzii or other anti-inflammatory commensals, were found to differ, so no such specific findings can be reported here.

What are the greatest implications of this study?

By applying two different 16S rRNA sequencing approaches in parallel, this pilot study demonstrates a strategy for more comprehensively capturing bacteria potentially associated with early and untreated T2D. The identification of microbiota signatures that discriminate prediabetes and treatment naive T2D from healthy states suggests the gut microbiota could eventually serve as a marker of disease status before or at diagnosis. As a pilot study, its findings point toward the value of larger, confirmatory studies to establish a reproducible T2D associated microbiota profile.

What was studied?

Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic dysfunction for which effective interventions are lacking. To investigate the effects of resistant starch (RS) as a microbiota-directed dietary supplement for NAFLD treatment, we coupled a 4-month randomized placebo-controlled clinical trial in individuals with NAFLD (ChiCTR-IOR-15007519) with metagenomics and metabolomics analysis. Relative to the control (n = 97), the RS intervention (n = 99) resulted in a 9.08% absolute reduction of intrahepatic triglyceride content (IHTC), which was 5.89% after adjusting for weight loss. Serum branched-chain amino acids (BCAAs) and gut microbial species, in particular Bacteroides stercoris, significantly correlated with IHTC and liver enzymes and were reduced by RS. Multi-omics integrative analyses revealed the interplay among gut microbiota changes, BCAA availability, and hepatic steatosis, with causality supported by fecal microbiota transplantation and monocolonization in mice. Thus, RS dietary supplementation might be a strategy for managing NAFLD by altering gut microbiota composition and functionality.

What was studied?

This study used metagenomic sequencing to characterize the gut microbiota of patients with non-segmental vitiligo. Researchers examined microbial community composition, diversity, and gene functions using bioinformatic analysis. They also predicted gut metabolic modules with the KEGG and MetaCyc databases to identify functional differences linked to the disease.

Who was studied?

The study enrolled 25 patients with non-segmental vitiligo and 25 matched healthy controls. All 50 participants underwent metagenomic sequencing of their gut microbiota for comparison between the two groups.

What were the most important findings?

Alpha diversity of the gut microbiome was significantly reduced in vitiligo patients compared with healthy controls. At the species level, Staphylococcus thermophiles was decreased while Bacteroides fragilis was increased in patients with vitiligo. LEfSe analysis identified additional microbial markers distinguishing vitiligo patients, including Lachnospiraceae_bacterium_BX3, Massilioclostridium_coli, and TM7_phylum_sp_oral_taxon_348, alongside Bacteroides_fragilis.

What are the greatest implications of this study?

These findings support a link between altered gut microbial composition and non-segmental vitiligo, reinforcing gut dysbiosis as a feature of the disease. The reduced diversity and specific species shifts, particularly the increase in Bacteroides fragilis, may serve as microbial markers for further investigation. Characterizing associated gene functions and metabolic modules could help clarify mechanisms connecting gut microbiota to vitiligo pathogenesis.

What was studied?

Chemoradiation (CRT) in patients with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including mucositis. The gut microbiome represents an emerging hallmark of cancer and a potentially important biomarker for CRT-related adverse events. This prospective study investigated the association between the gut microbiome composition and CRT-related toxicities in patients with HNSCC, including mucositis.

Who was studied?

Stool samples from patients diagnosed with locally advanced HNSCC were prospectively collected prior to CRT initiation and analyzed using shotgun metagenomic sequencing to evaluate gut microbiome composition at baseline. Concurrently, clinicopathologic data, survival outcomes and the incidence and grading of CRT-emergent adverse events were documented in all patients.

What were the most important findings?

A total of 52 patients were included, of whom 47 had baseline stool samples available for metagenomic analysis. Median age was 62, 83 % patients were men and 54 % had stage III-IV disease. All patients developed CRT-induced mucositis, including 42 % with severe events (i.e. CTCAE v5.0 grade ≥ 3) and 25 % who required enteral feeding. With a median follow-up of 26.5 months, patients with severe mucositis had shorter overall survival (HR = 3.3, 95 %CI 1.0-10.6; p = 0.02) and numerically shorter progression-free survival (HR = 2.8, 95 %CI, 0.8-9.6; p = 0.09). The gut microbiome beta-diversity of patients with severe mucositis differed from patients with grades 1-2 mucositis (p = 0.04), with enrichment in Mediterraneibacter (Ruminococcus gnavus) and Clostridiaceae family members, including Hungatella hathewayi. Grade 1-2 mucositis was associated with enrichment in Eubacterium rectale, Alistipes putredinis and Ruminococcaceae family members. Similar bacterial profiles were observed in patients who required enteral feeding.

What are the greatest implications of this study?

Patients who developed severe mucositis had decreased survival and enrichment in specific bacteria associated with mucosal inflammation. Interestingly, these same bacteria have been linked to immune checkpoint inhibitor resistance.

What was studied?

We explored the fecal microbiota in pediatric patients <18 years of age with treatment-naïve IBD (80 Crohn’s disease (CD), 27 ulcerative colitis (UC)), in 50 non-IBD patients with gastrointestinal symptoms without inflammation and in 75 healthy children. Using a targeted qPCR approach, the quantities of more than 100 different bacterial species were measured. Results: The bacterial abundance was statistically significantly reduced in the IBD and non-IBD patients compared to the healthy children for several beneficial species. The CD patients had a lower abundance of Bifidobacterium species compared to the UC patients, and the IBD patients in need of biologic therapy had a lower abundance of butyrate producing bacteria. Based on the abundance of bacterial species at diagnosis, we constructed Diagnostic, Phenotype and Prognostic Indexes. Patients with a high Diagnostic Index had 2.5 times higher odds for having IBD than those with a lower index. The CD patients had a higher Phenotype Index than the UC patients. Patients with a high Prognostic Index had 2.1 higher odds for needing biologic therapy compared to those with a lower index. Conclusions: The fecal abundance of bacterial species can aid in diagnosing IBD, in distinguishing CD from UC and in identifying children with IBD in need of biologic therapy.

What was studied?

This study investigated the ocular surface microbiome in patients with unilateral or asymmetric glaucoma who were using topical ophthalmic medications in only one eye. Researchers used V3-V4 16S rRNA sequencing on ocular surface swabs to characterize microbial diversity and composition. They then tested whether differences in microbial composition were related to measures of ocular surface disease, including tear meniscus height, tear break-up time, and Dry Eye Questionnaire scores.

Who was studied?

The study included 17 subjects total. Ten were patients with asymmetric or unilateral glaucoma who used topical glaucoma therapy in only one eye, allowing comparison between their treated and untreated eyes. Seven were age-matched healthy controls with no history of ocular disease or eyedrop use, and samples were grouped into three categories: treated glaucomatous eyes, untreated contralateral eyes, and healthy control eyes.

What were the most important findings?

Both the treated and the untreated eyes of glaucoma patients showed significantly greater alpha-diversity and a greater relative abundance of gram-negative organisms compared to healthy control eyes. This pattern occurred even in the contralateral eye that received no eyedrops, suggesting a systemic or bilateral effect rather than one confined to the treated eye alone. The microbial composition of patient eyes was also associated with decreased tear meniscus height and decreased tear break-up time, linking microbiome alterations to signs of ocular surface disease.

What are the greatest implications of this study?

The findings suggest that topical glaucoma therapy is associated with ocular surface microbiome shifts that extend beyond the directly treated eye, potentially through systemic exposure or shared tear film dynamics. Because these microbial changes correlated with impaired tear film stability, the results implicate the ocular surface microbiome as a factor in medication-related ocular surface disease among glaucoma patients. This raises the possibility that microbiome monitoring could inform strategies to reduce ocular surface complications in long-term glaucoma treatment.

What was studied?

The gut microbiome plays an important role in autoimmunity including multiple sclerosis and its mouse model called experimental autoimmune encephalomyelitis (EAE). Prior studies have demonstrated that the multiple sclerosis gut microbiota can contribute to disease, hence making it a potential therapeutic target. In addition, antibiotic treatment has been shown to ameliorate disease in the EAE mouse model of multiple sclerosis. Yet, to this date, the mechanisms mediating these antibiotic effects are not understood. Furthermore, there is no consensus on the gut-derived bacterial strains that drive neuroinflammation in multiple sclerosis.

What were the most important findings?

Here, we characterized the gut microbiome of untreated and vancomycin-treated EAE mice over time to identify bacteria with neuroimmunomodulatory potential. We observed alterations in the gut microbiota composition following EAE induction. We found that vancomycin treatment ameliorates EAE, and that this protective effect is mediated via the microbiota. Notably, we observed increased abundance of bacteria known to be strong inducers of regulatory T cells, including members of Clostridium clusters XIVa and XVIII in vancomycin-treated mice during the presymptomatic phase of EAE, as well as at disease peak. We identified 50 bacterial taxa that correlate with EAE severity. Interestingly, several of these taxa exist in the human gut, and some of them have been implicated in multiple sclerosis including Anaerotruncus colihominis, a butyrate producer, which had a positive correlation with disease severity. We found that Anaerotruncus colihominis ameliorates EAE, and this is associated with induction of RORγt+ regulatory T cells in the mesenteric lymph nodes.

What are the greatest implications of this study?

We identified vancomycin as a potent modulator of the gut-brain axis by promoting the proliferation of bacterial species that induce regulatory T cells. In addition, our findings reveal 50 gut commensals as regulator of the gut-brain axis that can be used to further characterize pathogenic and beneficial host-microbiota interactions in multiple sclerosis patients. Our findings suggest that elevated Anaerotruncus colihominis in multiple sclerosis patients may represent a protective mechanism associated with recovery from the disease. Video Abstract.

What was studied?

This study examined the gut microbiome in Parkinson's disease (PD) using large-scale, high-resolution shotgun metagenomic sequencing of fecal DNA. The researchers applied uniform, standardized methods throughout, followed by metagenome-wide association studies requiring agreement between two independent statistical methods (ANCOM-BC and MaAsLin2) before declaring a disease association. They also conducted network analysis to identify clusters of co-occurring microbial species and functional profiling to characterize microbial genes and pathways.

Who was studied?

The study enrolled 490 individuals with Parkinson's disease and 234 control individuals. Fecal samples from this cohort underwent deep shotgun sequencing to generate the metagenomic data analyzed in the study. The abstract does not provide further demographic detail on the participants.

What were the most important findings?

Over 30 percent of the species, genes, and pathways tested showed altered abundances in Parkinson's disease, indicating widespread dysbiosis. PD-associated species organized into polymicrobial clusters that grew, shrank, or competed together rather than acting independently. The PD microbiome was disease permissive: it showed overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, an excess of molecules that induce alpha-synuclein pathology, and overproduction of toxicants, alongside a reduction in anti-inflammatory and neuroprotective factors that would otherwise support recovery.

What are the greatest implications of this study?

By validating in human PD patients findings previously seen only in experimental models, this study strengthens the case that the gut microbiome contributes to multiple disease mechanisms in Parkinson's disease. The reconciliation of prior human PD microbiome literature helps resolve inconsistencies across earlier studies and establishes a more standardized foundation for future research. The reduction in anti-inflammatory and neuroprotective microbial factors points to a loss of protective capacity that may limit the body's ability to counteract disease processes, suggesting the microbiome as a potential target for future mechanistic and therapeutic investigation.

What was studied?

This study examined the gut microbial composition and structure associated with colorectal cancer (CRC) across populations from different geographic regions. Researchers used whole-genome sequencing (WGS) data, annotated with MetaPhlAn2, to determine species and genus level relative abundance. They applied PCA and LEfSe analysis to compare microbial differences between regional datasets and used Spearman correlation analysis to examine relationships among CRC-associated differential species. The ultimate goal was to build and verify CRC risk prediction models based on these regional microbial differences.

Who was studied?

The analysis drew on a metagenomic dataset of 601 samples collected from six countries, sourced from the GMrepo and NCBI databases. This represents a secondary analysis of previously generated whole-genome sequencing data rather than a newly recruited clinical cohort. The abstract does not specify individual patient demographics such as age or sex, only the multi-country, multi-sample composition of the dataset.

What were the most important findings?

The composition of the intestinal bacterial community varied by region, and the specific differential intestinal bacteria linked to CRC were inconsistent from country to country. Despite this regional variability, the researchers identified a common diversity of bacteria shared across all six countries, including Peptostreptococcus. These findings indicate that CRC-associated microbiota show both a conserved core signature and considerable geographic variation.

What are the greatest implications of this study?

The findings suggest that CRC risk prediction models based on gut microbiota may need to account for regional differences in microbial composition rather than assuming a universal signature. Identifying bacteria that are consistently associated with CRC across diverse populations, such as Peptostreptococcus, could support more broadly generalizable diagnostic or risk-assessment tools. At the same time, the region-specific differences highlight the importance of validating any microbiome-based CRC model within the population it will be applied to.

What was studied?

This study examined the composition and functional potential of the gut microbiota in people with type 2 diabetes (T2D) across two distinct populations, Denmark and South India. The researchers used 16S ribosomal RNA gene amplicon sequencing on stool samples to compare the gut microbiota between countries and between people with and without T2D. A central goal was to determine whether any microbiome signature of T2D is universal across ethnicities and diets, or whether such signatures are instead country-specific. The study also looked at microbial associations with treatment using the anti-hyperglycemic drug metformin.

Who was studied?

The study population consisted of 279 Danish study participants and 294 Indian study participants, for a total of 573 people. Stool samples were collected from both cohorts and profiled using 16S rRNA gene amplicon sequencing. The abstract does not specify additional demographic details such as age or sex distribution within these two national cohorts.

What were the most important findings?

The gut microbiota differed measurably between the Danish and Indian populations, reflecting country-specific patterns in diversity and composition. Samples were stratified to look for both global (trans-ethnic) and country-specific microbial signatures associated with T2D and with metformin treatment. This approach allowed the researchers to separate microbial features that might be universal markers of T2D from those that are shaped by local diet or ethnic background. The abstract does not report specific taxa, effect sizes, or statistical values for these comparisons.

What are the greatest implications of this study?

By directly comparing two ethnically and geographically distinct populations, this study helps clarify whether gut microbiota changes linked to type 2 diabetes represent a truly universal signature or are instead dependent on diet and ethnic origin. This distinction matters for whether microbiome-based diagnostics or interventions for T2D could be applied globally or would need to be tailored to specific populations. Separating country-specific findings from trans-ethnic ones also helps prevent overgeneralizing microbiome associations discovered in a single population. The findings support continued large-scale, multi-population microbiome research as a foundation for any future universal T2D biomarkers.

What was studied?

This study examined how SARS-CoV-2 infection affects the gut microbiome, looking at both the bacteriome and the virome together. The researchers investigated whether gut bacterial and viral communities shift during COVID-19 infection and whether these shifts relate to disease severity. They also used a mouse COVID-19 model to test whether SARS-CoV-2 infection alone could reproduce similar gut microbial changes and to examine immune and infection-related gene expression in gut epithelial cells.

Who was studied?

The human portion of the study involved a cohort of 13 COVID-19 patients in Beijing, China, compared with five healthy controls. Patients were further grouped by disease severity (mild to moderate versus severe) to compare gut bacteriome and virome composition. The findings from this human cohort were then replicated in a mouse model of COVID-19.

What were the most important findings?

The gut virome and bacteriome of COVID-19 patients were notably different from those of healthy controls, with a bacterial dysbiosis signature marked by reduced diversity and viral shifts. Among patients, bacterial and viral composition differed by disease severity, though these differences were not entirely separable from the effect of antibiotics. Severe cases showed a greater abundance of opportunistic pathogens and were depleted for butyrate-producing groups of bacteria compared with mild to moderate cases. The mouse model confirmed virome differences and bacteriome dysbiosis from SARS-CoV-2 infection, alongside differential expression of immune and infection-related genes in gut epithelial cells.

What are the greatest implications of this study?

The results suggest that SARS-CoV-2 infection measurably disrupts gut bacteriome and virome composition, not just respiratory tract microbiology. Because compositional signatures differed with severity, including depletion of butyrate-producing bacteria in severe cases, the gut microbiome may reflect or even contribute to disease severity and recovery. This points to the gut bacteriome and virome as a potential avenue for understanding COVID-19 progression and treatment outcomes, though the mixing of antibiotic effects with infection effects in the human cohort means further work is needed to disentangle these contributions.

What was studied?

This study examined changes in intestinal bacterial communities across healthy people, patients with inflammatory bowel disease (IBD), and patients with colorectal cancer (CRC). The researchers performed metagenome-wide association studies on fecal samples to characterize bacterial community structure, relative abundance, and functional predictions. They also analyzed differentially abundant bacteria and co-occurrence networks to compare the three groups.

Who was studied?

The analysis drew on fecal metagenomic data from 290 healthy subjects, 512 IBD patients, and 285 CRC patients. Healthy and CRC data were obtained from the European Nucleotide Archive under several study accession numbers, while IBD patient data came from the Integrated Human Microbiome Project via the Human Microbiome Project Data Portal. This makes the cohort a large, multi-source pooled metagenomic dataset rather than a single newly recruited study population.

What were the most important findings?

The bacterial community structure in both IBD and CRC patients differed significantly from that of healthy subjects. Notably, IBD patients showed low intestinal bacterial diversity, while CRC patients showed high intestinal bacterial diversity, a contrasting pattern between the two disease states. The abstract does not specify Faecalibacterium prausnitzii, butyrate, or other named commensals, so no claim is made about those organisms here.

What are the greatest implications of this study?

The finding that IBD and CRC involve opposite directions of diversity change suggests these two diseases are associated with distinct, rather than uniform, disruptions of the gut microbiome. This distinction could help refine how metagenomic diversity and community structure are used to distinguish disease states from health and from each other. It also underscores the value of large, pooled public metagenomic datasets for characterizing disease-associated microbial signatures.

What was studied?

This study examined the fecal gut metagenomes of three common intestinal diseases: Crohn's disease, ulcerative colitis, and colorectal cancer. The researchers performed a meta-analysis across 13 separate fecal metagenome data sets spanning these three conditions. Their goal was to identify microbial species and metabolic pathways that change consistently across multiple data sets for each disease, and to compare these signatures across diseases. They also built multidisease diagnostic models based on the markers they identified.

Who was studied?

The abstract does not describe a single new patient cohort but rather a meta-analysis pooling 13 existing fecal metagenome data sets covering Crohn's disease, ulcerative colitis, and colorectal cancer patients and controls. No specific sample sizes, ages, or geographic origins are given in the abstract. This can be honestly described as a secondary analysis of multiple public or previously published metagenomic cohorts rather than a single primary study population.

What were the most important findings?

The analysis identified 87 marker species and 65 marker pathways that were consistently altered across multiple data sets of the same disease. These markers grouped into disease-specific and disease-common clusters with distinct phylogenetic relationships: species specific to Crohn's disease were phylogenetically closely related, while colorectal cancer-specific species were more phylogenetically distant from one another. Notably, ulcerative colitis-specific species were phylogenetically closer to colorectal cancer-associated species, consistent with the known elevated colorectal cancer risk in ulcerative colitis patients. Marker species within the same cluster shared metabolic preferences, and disease cases showed more tightly coordinated microbial changes than controls, suggesting a more stressed, selective gut environment in disease states, with a subset of markers also correlating with an indicator of gut barrier (leaky gut) dysfunction.

What are the greatest implications of this study?

By mapping how disease-specific and disease-common microbial signatures relate phylogenetically and metabolically, this work supports the development of multidisease diagnostic models that could help distinguish between conditions with overlapping symptoms, such as Crohn's disease, ulcerative colitis, and colorectal cancer. The finding that ulcerative colitis markers resemble colorectal cancer markers phylogenetically offers a microbiome-based rationale for the elevated cancer risk seen in ulcerative colitis. The link between marker species and leaky gut indicators further ties gut dysbiosis to compromised intestinal barrier function. Overall, the study suggests cross-disease microbiome comparisons can sharpen diagnostic precision beyond single-disease marker panels.

What was studied?

This study examined whether the intestinal microbiome influences clinical outcome and treatment side effects in early breast cancer. Researchers used shotgun metagenomics to characterize fecal microbiota composition and paired this with plasma metabolomics. They looked at associations between the gut microbiota, measured at baseline and after chemotherapy, and both breast cancer prognosis and therapy-induced side effects. Findings were then tested for clinical relevance in an immunocompetent mouse model colonized with patient microbiota and challenged with mouse breast cancer and chemotherapy.

Who was studied?

The human cohort consisted of 76 early breast cancer patients contributing 121 fecal specimens, with 45 patients providing paired samples collected before and after chemotherapy. These patients were enrolled in the CANTO prospective study, which was designed to record side effects associated with clinical management of breast cancer. The findings were further validated in immunocompetent mice colonized with breast cancer patient microbiota.

What were the most important findings?

Specific gut commensals were found to be overabundant in breast cancer patients compared with healthy individuals. These overabundant commensals were associated with worse breast cancer prognosis. Chemotherapy modulated the abundance of these gut microbes, and the same microbes appeared to influence weight gain and neurological side effects linked to breast cancer therapies.

What are the greatest implications of this study?

The results suggest that gut microbiota composition could serve as a modifiable factor affecting both cancer prognosis and treatment tolerability in early breast cancer. Because chemotherapy itself reshapes these microbial communities, monitoring or targeting the microbiome during treatment may offer a way to improve outcomes and reduce side effects. The authors note that these findings, obtained in adjuvant and neoadjuvant settings, warrant prospective validation before any clinical application.

What was studied?

This study examined whether an ileal bile acid transporter inhibitor (IBATi), a drug developed to treat chronic idiopathic constipation, could improve nonalcoholic fatty liver disease (NAFLD) by acting on the gut microbiota. IBATi increases delivery of bile acids to the colon, and the researchers tested whether this shift in colonic bile acid exposure could alter gut bacteria in a way that benefits the liver. They measured body weight, liver function markers, serum lipids, NAFLD activity scores, and expression of bile-acid-related genes (Cyp7a1 in liver, Fgf15 in ileum) in high-fat diet (HFD) mice treated with IBATi.

Who was studied?

The subjects were mice fed a high-fat diet to induce a NAFLD model, with some receiving IBATi treatment alongside the HFD. Gut microbiota composition was assessed from fecal samples using 16S rRNA sequencing. A separate cohort of antibiotic-treated mice was recolonized through fecal microbiome transplantation (FMT) using stool from either HFD or HFD-plus-IBATi donor mice, allowing the researchers to test whether the microbiota itself could transfer the treatment effect.

What were the most important findings?

IBATi treatment significantly suppressed body weight gain, improved liver dysfunction, lowered serum LDL levels, and reduced NAFLD activity scores compared to untreated HFD mice. It also reversed HFD-induced decreases in hepatic Cyp7a1 and increased ileal Fgf15 expression, both markers of altered bile acid signaling. IBATi changed gut microbiota alpha-diversity that had been reduced by the high-fat diet, and this altered microbiota profile was able to be transferred to antibiotic-treated recipient mice via fecal transplantation.

What are the greatest implications of this study?

The findings suggest that redirecting bile acids to the colon with an ileal bile acid transporter inhibitor can improve hepatic steatosis largely through correction of gut microbiota dysbiosis, rather than through direct liver-only mechanisms. Because the FMT experiments show the microbiota changes themselves reproduce benefits, this supports the gut-liver axis as a therapeutic target for NAFLD. This positions IBATi, an already-used constipation drug, as a potential repurposed candidate for NAFLD treatment pending further research.

What was studied?

This study examined the gut microbiome composition of patients with young-onset colorectal cancer (yCRC), a form of sporadic colorectal cancer whose incidence is rising. Researchers used 16S rRNA gene sequencing to identify microbial markers distinguishing yCRC, then validated these findings in an independent cohort. Metagenome sequencing was also performed to characterize species-level and functional differences in bacterial communities associated with yCRC.

Who was studied?

The discovery analysis drew on 728 samples analyzed by 16S rRNA gene sequencing. An independent validation cohort of 310 samples was used to confirm the identified microbial markers. A further subset of 200 samples underwent metagenome sequencing for species-level and functional analysis.

What were the most important findings?

Gut microbial diversity was increased in yCRC compared to other groups studied. Flavonifractor plautii emerged as an important bacterial species associated with yCRC, whereas the genus Streptococcus contained the key phylotype linked to old-onset colorectal cancer. Functional analysis showed that yCRC-associated bacterial communities were distinguished by a dominance of DNA binding and RNA-dependent DNA biosynthetic processes, and a random forest classifier built on these microbial features achieved strong classification performance.

What are the greatest implications of this study?

The findings suggest that gut microbiota biomarkers, particularly Flavonifractor plautii abundance and associated functional signatures, could serve as a non-invasive tool for detecting and distinguishing yCRC. This approach could help address the diagnostic gap for younger patients as sporadic colorectal cancer incidence rises in this age group. The distinct microbial and functional profile of yCRC versus old-onset colorectal cancer also points to potentially different underlying disease biology between the two age groups.

What was studied?

Slow transit constipation (STC) is one of the most frequent gastrointestinal diagnoses. In this study, we conducted a quantitative metagenomics study in 118 Chinese individuals. These participants were divided into the discovery cohort of 50 patients with STC and 40 healthy controls as well as a validation cohort of 16 patients and 12 healthy controls. We found that the intestinal microbiome of patients with STC was significantly different from that of healthy individuals at the phylum, genus, and species level. Patients with STC had markedly higher levels of Alistipes and Eubacterium and lower abundance of multiple species belonging to the Roseburia genus. Patients with STC gene expression levels and the Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology pathway (such as fatty acid biosynthesis, butanoate metabolism, and methane metabolism pathways) enrichment were also substantially different from those of healthy controls. These microbiome and metabolite differences may be valuable biomarkers for STC. Our findings suggest that alteration of the microbiome may lead to constipation by changing the levels of microbial-derived metabolites in the gut. Above findings may help us in the development of microbial drugs.

What was studied?

The study characterised the relationships between gut microbiome composition, serum and faecal metabolites (including uraemic toxins and secondary bile acids), and clinical symptoms in end-stage renal disease (ESRD). Researchers used multidimensional data integration across microbiome, metabolome, and phenotype datasets to identify links between microbial functions and toxin accumulation. They then tested these relationships mechanistically using chronic kidney disease (CKD) rodent models, transplanting patient-derived microbiota into germ-free mice and antibiotic-treated rats to assess effects on toxin production and disease severity.

Who was studied?

The human portion of the study included a cohort of 223 patients with end-stage renal disease (ESRD) and 69 healthy controls. Gut microbiome, serum, and faecal metabolome data were collected from these individuals. The mechanistic portion of the study used renal-injured germ-free mice and antibiotic-treated rats as recipients of human-derived microbiota, rather than additional human subjects.

What were the most important findings?

A specific group of microbial species was enriched in ESRD patients and correlated tightly with clinical variables, and these species encoded functions involved in synthesizing uraemic toxins and secondary bile acids. The abundance of these microbial functions correlated with the serum and faecal concentrations of the corresponding metabolites. When microbiota from ESRD patients were transplanted into renal-injured germ-free mice or antibiotic-treated rats, the animals showed higher serum uraemic toxin production and more severe renal fibrosis and oxidative stress compared to animals receiving control microbiota. Two specific species, including Eggerthella lenta, were highlighted among those enriched in ESRD.

What are the greatest implications of this study?

The findings support a causal role for specific gut microbial species and their toxin-synthesizing functions in driving uraemic toxin accumulation and worsening renal injury, rather than the microbiome shift being merely a byproduct of kidney failure. This suggests that targeting these microbial species or their metabolic pathways could be a strategy to reduce toxin burden and slow renal fibrosis in ESRD patients. The transplantation experiments in rodents strengthen the case that gut-derived microbial functions have a direct, testable effect on host kidney disease severity.

What was studied?

Parkinson's disease (PD) is a systemic disease clinically defined by the degeneration of dopaminergic neurons in the brain. While alterations in the gut microbiome composition have been reported in PD, their functional consequences remain unclear. Herein, we addressed this question by an analysis of stool samples from the Luxembourg Parkinson's Study (n = 147 typical PD cases, n = 162 controls).

What were the most important findings?

All individuals underwent detailed clinical assessment, including neurological examinations and neuropsychological tests followed by self-reporting questionnaires. Stool samples from these individuals were first analysed by 16S rRNA gene sequencing. Second, we predicted the potential secretion for 129 microbial metabolites through personalised metabolic modelling using the microbiome data and genome-scale metabolic reconstructions of human gut microbes. Our key results include the following. Eight genera and seven species changed significantly in their relative abundances between PD patients and healthy controls. PD-associated microbial patterns statistically depended on sex, age, BMI, and constipation. Particularly, the relative abundances of Bilophila and Paraprevotella were significantly associated with the Hoehn and Yahr staging after controlling for the disease duration. Furthermore, personalised metabolic modelling of the gut microbiomes revealed PD-associated metabolic patterns in the predicted secretion potential of nine microbial metabolites in PD, including increased methionine and cysteinylglycine. The predicted microbial pantothenic acid production potential was linked to the presence of specific non-motor symptoms.

What are the greatest implications of this study?

Our results suggest that PD-associated alterations of the gut microbiome can translate into substantial functional differences affecting host metabolism and disease phenotype.

What was studied?

Lysine acetylation (Kac), an abundant post-translational modification (PTM) in prokaryotes, regulates various microbial metabolic pathways. However, no studies have examined protein Kac at the microbiome level, and it remains unknown whether Kac level is altered in patient microbiomes. Herein, we use a peptide immuno-affinity enrichment strategy coupled with mass spectrometry to characterize protein Kac in the microbiome, which successfully identifies 35,200 Kac peptides from microbial or human proteins in gut microbiome samples. We demonstrate that Kac is widely distributed in gut microbial metabolic pathways, including anaerobic fermentation to generate short-chain fatty acids. Applying to the analyses of microbiomes of patients with Crohn's disease identifies 52 host and 136 microbial protein Kac sites that are differentially abundant in disease versus controls. This microbiome-wide acetylomic approach aids in advancing functional microbiome research.

What was studied?

This study examined whether the composition of the gut microbiota differs between children with acute lymphoblastic leukemia (ALL) and healthy children. Fecal samples were analyzed using 16S rRNA quantitative arrays combined with bioinformatics analysis. The researchers compared overall community structure using Principal Coordinates Analysis (PCoA) and Non-metric Multidimensional Scaling (NMDS), and then looked for individual bacterial species that distinguished the two groups.

Who was studied?

The study included 81 subjects total, comprising 58 pediatric patients with acute lymphoblastic leukemia and 23 healthy children serving as controls. All participants provided fecal samples for microbiota analysis. The abstract does not specify additional demographic details such as age range, sex distribution, or geographic location.

What were the most important findings?

PCoA and NMDS both showed that the microbial composition of ALL patients deviated from the tight cluster formed by healthy controls, indicating a distinct gut microbiota profile in disease. Multiple bacterial species showed significant changes in abundance in ALL samples, including Roseburia faecis, Edwardsiella tarda, and Fusobacterium naviforme. Some of these differentially abundant taxa were correlated with interleukin-10 levels, suggesting a link between microbiota shifts and immune signaling. A random forest model built on these differential species distinguished ALL cases from healthy controls with good accuracy (area under the ROC curve of 0.843).

What are the greatest implications of this study?

The findings suggest that childhood ALL is accompanied by a characteristic, measurable alteration in the gut microbiota rather than a random or negligible shift. The correlation between specific taxa and interleukin-10 raises the possibility that these microbial changes are connected to immune regulation in ALL patients. The strong classification performance of the random forest model suggests gut microbiota profiling could eventually contribute to distinguishing ALL cases from healthy children, supporting further investigation into microbiota-based biomarkers for this disease.

What was studied?

This study asked whether gut microbiome signatures linked to colorectal cancer (CRC) hold up reliably across different patient cohorts and populations. The researchers meta-analyzed fecal metagenomic sequencing data to identify microbial taxa and functional pathways that consistently distinguish CRC from controls. They also examined the microbiome's functional potential, comparing metabolic pathways such as gluconeogenesis, putrefaction, fermentation, and choline degradation between CRC and control samples. Finally, they built and tested predictive microbiome signatures for CRC diagnosis.

Who was studied?

The analysis drew on 969 fecal metagenomes assembled from five publicly available datasets plus two newly collected cohorts, with findings further validated on two additional independent cohorts. The abstract does not specify demographic details such as age, sex, or geographic origin of participants. This design represents a large-scale, multi-population pooling of existing and new CRC and control stool metagenome datasets rather than a single defined patient group.

What were the most important findings?

The gut microbiome in CRC showed reproducibly higher richness than in controls (P < 0.01), partly driven by expansions of species normally derived from the oral cavity. Functional meta-analysis linked gluconeogenesis and putrefaction/fermentation pathways to CRC, while stachyose and starch degradation pathways were associated with controls. A predictive microbiome signature trained across multiple datasets achieved consistently high accuracy in datasets and independent validation cohorts it had not been trained on, with an average area under the curve of 0.84. Pooled raw metagenome analysis also found the choline trimethylamine-lyase gene overabundant in CRC samples (P = 0.001), linking microbiome choline metabolism to CRC.

What are the greatest implications of this study?

By validating microbial richness increases, specific functional pathway shifts, and a diagnostic signature across multiple independent cohorts, this study strengthens the case that gut microbiome-based biomarkers for CRC can generalize beyond a single population. The identification of an overabundant choline trimethylamine-lyase gene points to microbiome-driven choline degradation as a mechanistic link worth further investigation in CRC. The high, cross-cohort predictive accuracy (AUC 0.84) supports the feasibility of microbiome-based tools as non-invasive adjuncts for CRC screening or risk stratification.

What was studied?

This study examined how long-term cotrimoxazole prophylaxis reduces systemic inflammation in HIV infection, a known independent driver of HIV-related mortality. Researchers investigated whether cotrimoxazole's clinical benefits could be explained by changes in the gut microbiome and intestinal inflammatory biomarkers, since subclinical enteropathogen carriage and enteropathy can drive systemic inflammation. They also used in vitro models of systemic and intestinal inflammation to isolate direct immune effects of cotrimoxazole from its antibiotic effects on gut bacteria.

Who was studied?

The study population was HIV-positive Ugandan and Zimbabwean children receiving antiretroviral therapy. Plasma inflammatory markers were compared between children randomized to continue cotrimoxazole (n = 144) versus stop it (n = 149). A smaller subset underwent gut microbiome and fecal biomarker analysis, with 36 children continuing cotrimoxazole compared to 36 stopping it.

What were the most important findings?

Plasma inflammatory markers were lower in children who continued cotrimoxazole compared to those who stopped, and this difference was not explained by clinical illness, HIV progression, or nutritional status. Overall gut microbiome composition was unchanged, but viridans group Streptococci and streptococcal mevalonate pathway enzymes were lower among children continuing cotrimoxazole. These microbial changes were associated with lower fecal myeloperoxidase, an intestinal inflammatory biomarker, and in vitro experiments showed cotrimoxazole had modest but consistent direct inhibitory effects on proinflammatory cytokine production.

What are the greatest implications of this study?

The findings suggest cotrimoxazole prophylaxis reduces systemic inflammation in HIV infection through a combination of altering specific gut bacterial populations and directly dampening immune activation, rather than through broad microbiome restructuring. Targeting streptococcal populations and intestinal inflammation, alongside direct anti-inflammatory drug effects, may be a mechanism underlying reduced HIV-related mortality and morbidity. This dual mechanism could inform strategies to further optimize prophylactic approaches in HIV-positive populations on antiretroviral therapy.

What was studied?

Cross talk occurs between the human gut and the lung through a gut-lung axis involving the gut microbiota. However, the signatures of the human gut microbiota after active Mycobacterium tuberculosis infection have not been fully understood. Here, we investigated changes in the gut microbiota in tuberculosis (TB) patients by shotgun sequencing the gut microbiomes of 31 healthy controls and 46 patients. We observed a dramatic changes in gut microbiota in tuberculosis patients as reflected by significant decreases in species number and microbial diversity. The gut microbiota of TB patients were mostly featured by the striking decrease of short-chain fatty acids (SCFAs)-producingbacteria as well as associated metabolic pathways. A classification model based on the abundance of three species, Haemophilus parainfluenzae, Roseburia inulinivorans, and Roseburia hominis, performed well for discriminating between healthy and diseased patients. Additionally, the healthy and diseased states can be distinguished by SNPs in the species of B. vulgatus. We present a comprehensive profile of changes in the microbiota in clinical TB patients. Our findings will shed light on the design of future diagnoses and treatments for M. tuberculosis infections.

What was studied?

This study investigated the gut microbiome and metabolome in colorectal cancer (CRC) to test whether host-microbiome associations found in prior research, mostly from developed countries, also hold in a distinct population. Researchers performed metagenomic and metabolomic analyses of fecal samples, then compared their results with CRC microbiome data available from other populations. The focus was on identifying bacterial taxa and metabolic pathways linked to CRC in a setting where the disease has historically been rare.

Who was studied?

The study analyzed fecal samples from 30 colorectal cancer patients and 30 healthy controls recruited from two different locations in India. This population was chosen specifically because India has a low incidence of colorectal cancer and a distinct diet, lifestyle, and gut microbiome compared to other global populations. Data from this Indian cohort were also compared against previously published CRC microbiome datasets from other countries.

What were the most important findings?

The researchers confirmed that Bacteroides and other bacterial taxa already linked to CRC in earlier studies were also associated with CRC in this Indian cohort. A novel finding was the association of Flavonifractor plautii, a flavonoid-degrading bacterium, with CRC in these patients. This association correlated with enzymes and metabolic modules involved in flavonoid degradation, suggesting a link between the breakdown of beneficial anticarcinogenic flavonoids and the disease. The team also identified 20 potential microbial taxonomic markers and 33 potential microbial gene markers that distinguished CRC from healthy microbiomes with high accuracy using machine learning.

What are the greatest implications of this study?

The findings suggest that loss of beneficial, flavonoid-degrading control (via F. plautii) may contribute to cancer progression in this Indian cohort, expanding the known microbial players beyond previously identified taxa like Bacteroides. Because India has unusually low CRC incidence alongside a distinct gut microbiome, these cohort-specific biomarkers may not generalize globally and highlight the need for population-specific microbiome research. The taxonomic and gene markers identified could also support development of noninvasive, microbiome-based diagnostic tools for CRC in diverse populations.

What was studied?

Anti-PD-1-based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients' microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16S ribosomal RNA gene sequencing, metagenomic shotgun sequencing, and quantitative polymerase chain reaction for selected bacteria. A significant association was observed between commensal microbial composition and clinical response. Bacterial species more abundant in responders included Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium. Reconstitution of germ-free mice with fecal material from responding patients could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti-PD-L1 therapy. Our results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients.

What was studied?

The study investigated how fecal microbiota metabolize non-digestible oligo- and polysaccharides, using isothermal microcalorimetry to track fermentation in real time. Five substrates were tested: raffinose, melibiose, an oligo- and polysaccharide mixture produced from raffinose by levansucrase, levan synthesized from raffinose, and levan from timothy grass. Growth was assessed from heat evolution curves along with organic acid and gas production, and taxonomic shifts were profiled by 16S rDNA sequencing.

Who was studied?

The work used pooled fecal samples as inocula rather than individual human subjects tested directly. Three fecal pools were compared: one from overweight children, one from normal-weight children, and one from healthy adult volunteers. A pure culture of Bacteroides thetaiotaomicron was included as a reference colon bacterium alongside these pooled samples.

What were the most important findings?

Raffinose and melibiose promoted bifidobacteria growth across all three fecal pools, but each pool showed distinct additional responses. In the overweight children's pool, lactate-producing bacteria such as Streptococcus and Enterococcus became enriched, making lactic acid the dominant fermentation product from the short saccharides. In the normal-weight children's pool, acetic and butyric acids predominated instead, coinciding with enrichment of Catenibacterium, while in the adult pool the levans specifically promoted Bacteroides and Lachnospiraceae.

What are the greatest implications of this study?

The findings indicate that fecal microbiota from overweight versus normal-weight children ferment the same prebiotic-type substrates into different metabolic end products, not just different taxa. Because overweight children's microbiota favored lactic acid production over the acetate and butyrate seen in normal-weight children, substrate choice and host metabolic status together shape fermentation outcomes. This suggests that prebiotic selection may need to be tailored by weight status or metabolic phenotype rather than applied uniformly across pediatric populations.

What was studied?

This study evaluated whether faecal metagenomes could be used to diagnose colorectal cancer (CRC) non-invasively. Researchers performed metagenome-wide association studies on stool samples to identify microbial species and gene markers associated with CRC. They then tested whether a small set of these markers could reliably distinguish CRC patients from controls using both metagenomic sequencing and targeted quantitative PCR (qPCR) assays. The candidate biomarkers were validated across multiple independent cohorts from different countries.

Who was studied?

The primary cohort included 74 patients with CRC and 54 controls from China. Validation cohorts included 16 CRC patients and 24 controls from Denmark, plus two previously published cohorts from France and Austria. A further independent Chinese cohort of 47 patients with CRC and 109 controls was used for qPCR-based validation.

What were the most important findings?

The study confirmed known associations between CRC and Fusobacterium nucleatum and Peptostreptococcus stomatis, and identified new associations with species including Parvimonas micra and Solobacterium moorei. Researchers identified 20 microbial gene markers differentiating CRC and control microbiomes, of which 4 were validated in the Danish cohort. These four genes distinguished CRC from controls in the French and Austrian cohorts with AUCs of 0.72 and 0.77, and qPCR measurement of two of these genes classified CRC patients in an independent Chinese cohort with an AUC of 0.84 and an odds ratio of 23.

What are the greatest implications of this study?

These findings suggest that faecal microbial gene markers, including some detectable at early cancer stages, could serve as non-invasive biomarkers for CRC screening. Validation across cohorts from China, Denmark, France, and Austria supports the generalizability of a small panel of markers across different populations. Because qPCR is a simple, targeted assay, these markers may be practical to develop into a clinical diagnostic test for CRC.

What was studied?

This study examined how different combined antiretroviral therapy (cART) regimens affect bacterial translocation and gut microbiota composition in HIV-infected patients. Prior work had shown that increased bacterial translocation and altered gut microbiota persist in HIV infection despite cART, contributing to immune activation and inflammation, but the role of specific drug combinations had not been investigated. Researchers measured soluble markers of bacterial translocation and inflammation and analyzed gut microbiota using 16S rDNA pyrosequencing (Illumina MiSeq).

Who was studied?

The cross-sectional study included 45 HIV-infected patients on cART, divided into three regimen groups: NRTIs plus protease inhibitors (n = 15), NRTIs plus non-nucleoside reverse transcriptase inhibitors (n = 22), and NRTIs plus integrase strand transfer inhibitors (INSTIs, n = 8). Also included were 5 untreated HIV-infected patients and 21 non-infected volunteers as comparison groups.

What were the most important findings?

The NRTIs plus INSTIs regimen was associated with systemic inflammation levels similar to those seen in uninfected controls, distinguishing it from the other cART combinations. HIV infection was linked to a reduction in fecal bacterial diversity. The abstract text was truncated, so further comparative details on translocation markers and microbiota composition across regimens are not available here.

What are the greatest implications of this study?

The findings suggest that the specific composition of a cART regimen, not just cART use in general, may influence residual inflammation and gut microbiota disruption in people living with HIV. This raises the possibility that regimens including INSTIs could offer advantages for reducing systemic inflammation compared to other combinations. Further research is needed to confirm these differential effects and clarify their clinical significance.

What was studied?

It is well known that the microbiota of high-fat (HF) diet-induced obese mice differs from that of lean mice, but to what extent, this difference reflects the obese state or the diet is unclear. To dissociate changes in the gut microbiota associated with high HF feeding from those associated with obesity, we took advantage of the different susceptibility of C57BL/6JBomTac (BL6) and 129S6/SvEvTac (Sv129) mice to diet-induced obesity and of their different responses to inhibition of cyclooxygenase (COX) activity, where inhibition of COX activity in BL6 mice prevents HF diet-induced obesity, but in Sv129 mice accentuates obesity.

What were the most important findings?

Using HiSeq-based whole genome sequencing, we identified taxonomic and functional differences in the gut microbiota of the two mouse strains fed regular low-fat or HF diets with or without supplementation with the COX-inhibitor, indomethacin. HF feeding rather than obesity development led to distinct changes in the gut microbiota. We observed a robust increase in alpha diversity, gene count, abundance of genera known to be butyrate producers, and abundance of genes involved in butyrate production in Sv129 mice compared to BL6 mice fed either a LF or a HF diet. Conversely, the abundance of genes involved in propionate metabolism, associated with increased energy harvest, was higher in BL6 mice than Sv129 mice.

What are the greatest implications of this study?

The changes in the composition of the gut microbiota were predominantly driven by high-fat feeding rather than reflecting the obese state of the mice. Differences in the abundance of butyrate and propionate producing bacteria in the gut may at least in part contribute to the observed differences in obesity propensity in Sv129 and BL6 mice.

What was studied?

The global alteration of the gut microbial community (dysbiosis) plays an important role in the pathogenesis of inflammatory bowel diseases (IBDs). However, bacterial species that characterize dysbiosis in IBD remain unclear. In this study, we assessed the alteration of the fecal microbiota profile in patients with Crohn's disease (CD) using 16S rRNA sequencing.

What was studied?

Cross-sectional studies suggested that obesity is promoted by the gut microbiota. However, longitudinal data on taxonomic and functional changes in the gut microbiota of obese patients are scarce. The aim of this work is to study microbiota changes in the course of weight loss therapy and the following year in obese individuals with or without co-morbidities, and to asses a possible predictive value of the gut microbiota with regard to weight loss maintenance.

Who was studied?

Sixteen adult patients, who followed a 52-week weight-loss program comprising low calorie diet, exercise and behavioral therapy, were selected according to their weight-loss course. Over two years, anthropometric and metabolic parameters were assessed and microbiota from stool samples was functionally and taxonomically analyzed using DNA shotgun sequencing.

What were the most important findings?

Overall the microbiota responded to the dietetic and lifestyle intervention but tended to return to the initial situation both at the taxonomical and functional level at the end of the intervention after one year, except for an increase in Akkermansia abundance which remained stable over two years (12.7x103 counts, 95%CI: 322-25100 at month 0; 141x103 counts, 95%CI: 49-233x103 at month 24; p = 0.005). The Firmicutes/Bacteroidetes ratio was higher in obese subjects with metabolic syndrome (0.64, 95%CI: 0.34-0.95) than in the "healthy obese" (0.27, 95%CI: 0.08-0.45, p = 0.04). Participants, who succeeded in losing their weight consistently over the two years, had at baseline a microbiota enriched in Alistipes, Pseudoflavonifractor and enzymes of the oxidative phosphorylation pathway compared to patients who were less successful in weight reduction.

What are the greatest implications of this study?

Successful weight reduction in the obese is accompanied with increased Akkermansia numbers in feces. Metabolic co-morbidities are associated with a higher Firmicutes/Bacteroidetes ratio. Most interestingly, microbiota differences might allow discrimination between successful and unsuccessful weight loss prior to intervention.

What was studied?

This study examined whether fecal microbiota composition could serve as a non-invasive marker for detecting colorectal cancer (CRC). Researchers used metagenomic sequencing of stool samples to identify taxonomic markers distinguishing CRC patients from tumor-free controls. They then compared the accuracy of this metagenomic approach to the standard fecal occult blood test (FOBT), including a combined-test strategy. The study also explored whether fecal microbial changes reflected microbial community shifts at the tumor site itself, along with associated metabolic changes.

Who was studied?

The initial study population comprised 156 participants whose fecal samples were profiled by metagenomic sequencing to build the taxonomic marker panel. The findings were then validated in independent patient and control populations totaling 335 individuals from different countries. Together, the cohorts spanned both early- and late-stage CRC cases alongside tumor-free controls, though the abstract does not specify age, sex, or other demographic details.

What were the most important findings?

Metagenomic detection of CRC performed similarly to the standard FOBT, and combining the two approaches improved sensitivity by more than 45 percent relative to FOBT alone while maintaining its specificity. Detection accuracy did not differ significantly between early- and late-stage cancer, and the results were validated across independent populations from different countries. CRC-associated fecal microbiome changes partly mirrored microbial community composition at the tumor itself, suggesting tumor-related host-microbe interactions. The data also indicated a metabolic shift from fiber degradation in controls to utilization of host carbohydrates and amino acids in CRC patients, accompanied by increased lipopolysaccharide metabolism.

What are the greatest implications of this study?

These findings suggest fecal metagenomic profiling could serve as a non-invasive, early-stage screening tool for colorectal cancer, particularly when combined with existing tests like FOBT to boost sensitivity without sacrificing specificity. The ability to detect early-stage cancer as reliably as late-stage disease points to potential use in earlier intervention and improved outcomes. The parallel between fecal and tumor-associated microbial shifts, along with a metabolic move toward host-carbohydrate and amino-acid utilization and elevated lipopolysaccharide metabolism, implicates the gut microbiome as an active participant in tumor-related host-microbe interactions rather than a passive bystander. This reinforces the rationale for further validation of microbiome-based screening across broader, more diverse populations.

What was studied?

The involvement of the gut microbiota in metabolic disorders, and the ability of whole grains to affect both host metabolism and gut microbial ecology, suggest that some benefits of whole grains are mediated through their effects on the gut microbiome. Nutritional studies that assess the effect of whole grains on both the gut microbiome and human physiology are needed. We conducted a randomized cross-over trial with four-week treatments in which 28 healthy humans consumed a daily dose of 60 g of whole-grain barley (WGB), brown rice (BR), or an equal mixture of the two (BR+WGB), and characterized their impact on fecal microbial ecology and blood markers of inflammation, glucose and lipid metabolism. All treatments increased microbial diversity, the Firmicutes/Bacteroidetes ratio, and the abundance of the genus Blautia in fecal samples. The inclusion of WGB enriched the genera Roseburia, Bifidobacterium and Dialister, and the species Eubacterium rectale, Roseburia faecis and Roseburia intestinalis. Whole grains, and especially the BR+WGB treatment, reduced plasma interleukin-6 (IL-6) and peak postprandial glucose. Shifts in the abundance of Eubacterium rectale were associated with changes in the glucose and insulin postprandial response. Interestingly, subjects with greater improvements in IL-6 levels harbored significantly higher proportions of Dialister and lower abundance of Coriobacteriaceae. In conclusion, this study revealed that a short-term intake of whole grains induced compositional alterations of the gut microbiota that coincided with improvements in host physiological measures related to metabolic dysfunctions in humans.

What was studied?

This study investigated how the composition of the human intestinal microbiota relates to intestinal permeability and both local and systemic inflammation in obesity. Researchers profiled fecal microbiota using a phylogenetic microarray and compared this to markers of gut and whole-body inflammation. They also assessed gastroduodenal, small intestinal, and colonic permeability using a multisaccharide test, alongside metabolic markers such as HbA1c, transaminases, and lipids.

Who was studied?

The study population consisted of 28 subjects spanning a wide BMI range of 18.6 to 60.3 kg/m2, covering both nonobese and obese individuals. Based on microbiota composition, these subjects segregated into two clusters: one made up predominantly of obese participants (15 of 19) and another made up exclusively of nonobese participants (9 of 9). This design allowed comparison of inflammatory and permeability measures across microbiota-defined groups rather than by BMI category alone.

What were the most important findings?

Intestinal permeability did not differ between the two microbiota clusters, but the obese-predominant cluster showed reduced bacterial diversity, a decreased Bacteroidetes to Firmicutes ratio, and an increased abundance of potentially proinflammatory Proteobacteria. Fecal calprotectin, a marker of intestinal inflammation, was only detectable in a subset of subjects within the obese microbiota cluster (8 of 19, P = 0.02). Plasma C-reactive protein, a marker of systemic inflammation, was also increased in these subjects, linking microbiota composition to both local and systemic inflammatory signals.

What are the greatest implications of this study?

The findings suggest that a distinct, less diverse microbiota profile enriched in Proteobacteria and depleted in Bacteroidetes relative to Firmicutes is associated with detectable gut and systemic inflammation in some obese individuals, independent of measured intestinal permeability. This points to microbiota composition, rather than barrier leakiness alone, as a candidate driver or marker of the inflammatory state seen in obesity. These results support further work on microbiota-targeted strategies to address obesity-associated inflammation.